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ABSTRACT
THE ANTI.OBESOGENIC EFFECTS OF NITRIC OXIDE
Brian E. Sansbury
April 22, 2014
Obesity is a strong risk factor for developing type 2 diabetes and cardiovascular
disease and has quickly reached epidemic proportions with few tangible and safe
treatment options. While it is generally accepted that the primary cause of obesity
is energy imbalance, i.e., more calories are consumed than are utilized,
understanding how caloric balance is regulated has proven a challenge.
Molecular processes and pathways that directly regulate energy metabolism
represent promising targets for therapy. In particular, nitric oxide (NO) is
emerging as a central regulator of energy metabolism and body composition. NO
bioavailability is decreased in animal models of obesity and in obese and insulin
resistant patients, and increasing NO output has remarkable effects on obesity
and insulin resistance. Additionally, deletion of eNOS (the source of NO in the
vasculature) is associated with adiposity, insulin resistance and impaired fatty
acid oxidation. The role of eNOS in regulating metabolism, however, is not well
understood. We propose that decreased vascular-derived NO bioavailability
during nutrient excess is a critical development that leads to metabolic
dysregulation. The studies presented here show that obesity induces severe
iv

GRAPHICAL ABSTRACT

Modified from: Leonardo DaVinci’s Vitruvian Man, courtesy of Thomas P. Gorton

v

metabolic changes in adipose tissue including profound decreases in eNOS
abundance. Overexpression of eNOS prevents obesity and its related metabolic
alterations while causing significant changes in energy expenditure and systemic
metabolism. Our findings reveal potent anti-obesogenic effects of NO and
demonstrate a significant role for NO in regulating metabolism.
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CHAPTER I
GENERAL INTRODUCTION

The Obesity Epidemic
The recent increase in the prevalence of obesity is alarming. The Centers
for Disease Control and Prevention (CDC) estimate that from 1962 to 2010
prevalence of obesity has increased from 13% to 36%. In 2008, approximately
1.5 billion adults aged 20 years or older were overweight, and 10% were obese 1;
more recent data from the United States indicate that >33% of adults and 17% of
children are obese 2. This has led to a dramatic increase in individuals with prediabetes. For example, current estimates indicate that one-third of the population
in the US meets the criteria for pre-diabetes

3, 4

, and, in addition to type 2

diabetes (T2D), obesity is closely associated with co-morbidities such as
coronary artery disease, hypertension, atherosclerosis, stroke, and cancer 5.
Hence, the current high prevalence of obesity is likely to have a considerable
impact on worldwide health.

In the US, the economic burden of obesity is

substantial and accounts for an estimated $147 billion per year 6. The problem
has become so severe that, in 2013, the American Medical Association House of
Delegates declared obesity a disease.

1

The principal cause of obesity is energy imbalance: the calories consumed
are greater than that utilized by bodily processes, e.g., breathing, digestion,
thermogenesis and mechanical work 7. Indeed, the average consumption of
calories in the US increased by >200 kcal/d per person from 1971-2000, which is
partly attributable to the abundance of affordable, widely marketed, energy-dense
foods

8-11

. Nevertheless, evidence suggests that the balance between calorie

intake and energy expenditure is complex and regulated by many factors.
Exposure to increasingly obesogenic environments has been suggested to
promote not only overeating, but inactivity as well. For example, the human
environment is fraught with both chemical and structural “obesogens.” These
include but are not limited to: pollutants that promote adiposity and insulin
resistance

12-21

; lack of structural features of the built environment that promote

an active lifestyle, such as easy access to parks, sidewalks, and bike paths

22-24

;

and the night/day cycles in the natural environment of the individual, which can
be altered in those having certain occupations

25-27

. Moreover, the genetic

makeup of individuals shows strong associations with the predisposition to
become obese 28-30.
Many of these factors influence body composition in an indirect or distal manner,
and thus could be considered “distal causes” of obesity (Fig. 1). Interventions to
mitigate the effects of these distal causes are exceedingly difficult to test and
implement. For example, changing the structural environment would likely entail
departing from particular types of communities or neighborhoods. Similarly, living
under favorable day-night cycles is difficult for workers in some occupations, and
2

Figure 1. Distal and proximal causes of obesity. Influencing factors distal to
the disease, such as policy as well as structural and chemical “obesogens” of the
built and social (cultural) environment, may contribute to the prevalence of
obesity. Funding for obesity research, dietary guidelines, physical education
policies, and sidewalk standards are examples of potential influences related to
Policy, which is most distal to the actual disease. The Built environment, which
comprises places created or modified by people—i.e., where individuals work,
their transportation systems, and life outside their homes—is another cause
distal to obesity. The Social or cultural environment includes those family or
cultural influences that affect behavioral activity, occupation (which may involve
shift work), and social and media norms, all of which could affect eating habits
and physical activity.

Lastly, direct mechanisms that control hunger, satiety,

energy expenditure, and nutrient absorption are Proximal causes of obesity.
Commonly, these proximal causes are more tangible targets for antiobesity/diabetes therapies compared with distal causes.

3

4

changing genetic makeup is currently not an option. Even weight loss via caloric
restriction faces difficulties, including an evolution-engendered guard against low
fat mass
dieting

7, 31

and the propensity of the body to increase caloric efficiency during

32, 33

. The intransigency of these problems has led to a search for causes

more proximal to obesity, which may be tangible targets for anti-obesity
therapies.

Obesity, Insulin Resistance and Type 2 Diabetes
The World Health Organization (WHO) defines obesity as abnormal or
excessive fat accumulation that may impair health and is characterized by a body
mass index (BMI) equal to or greater than 30 kg/m 2. Evidence from numerous
studies has demonstrated that obesity and increased weight gain are strongly
associated with an increased risk of T2D
decreases that risk

34-36

and that intentional weight loss

37

. T2D is characterized by chronic hyperglycemia with

disturbances of carbohydrate, protein and fat metabolism resulting from defects
in insulin secretion, action or both

38

. While a causal link between obesity and

diabetes remains to be fully clarified, their association is undeniable.
Development

of

effective

treatments,

therefore,

depends

on

greater

understanding of the metabolic dysregulation that accompanies the onset of
obesity and its progression to insulin resistance and diabetes.

5

Metabolic pathways known to regulate obesity
Understanding the mechanisms that promote adiposity and insulin resistance
are critical to stem the growing tide of metabolic disease.

In particular, the

development of therapies for obesity and T2D requires a better understanding of
the biochemical pathways that regulate metabolism and body composition. As a
first principle, energy balance must be considered to understand how changes in
body composition could occur. Any effective obesity treatment must decrease
energy intake, increase energy expenditure or both. Systems that regulate
energy balance include:
1) Hunger and satiety: The central nervous system regulates caloric intake
and the feeling of satisfaction or fullness after a meal, i.e., satiety. This
regulation is dependent on neural and endocrine inputs that can be
divided

into

short-

and

long-term

control

systems.

Release

of

cholecystokinin (CCK) in combination with neural signaling in response to
gut distension are potent signals of satiety and trigger an end to feeding

39

.

The adipose tissue-derived hormone, leptin, is crucial to integrate the
melanocortin neuronal circuit of the hypothalamus with the energy stores
of the body 39-41. In addition to leptin, neuropeptide Y (NPY) directly affects
feeding behavior, metabolism and body composition
corticotropin-releasing

hormone,

42,

growth-hormone-releasing

43

, and

hormone,

galanin and ghrelin, some of which are expressed in both the stomach and
the

brain,

function

in

hunger

and

6

satiety

signaling

44

.

The

neurotransmitters norepinephrine, dopamine and serotonin are also
important in central energy balance

39, 41

and inhibiting their reuptake by

drugs such as sibutramine, has proven anti-obesogenic effects but leads
to side effects such as increased blood pressure and heart rate

45

. Other

drugs that have been shown to be effective in decreasing energy intake by
suppressing appetite 7, 46, 47.
2) Nutrient absorption: Targeting nutrient absorption in the gut may be an
effective obesity therapy. Signals from the gut released post-prandially are
important not only in regulating food intake, but also in digestion and
nutrient absorption. Ghrelin and CCK, as well as, peptide YY, glucagonlike peptides 1 and 2, gastric inhibitory peptide and corticotropin-releasing
factor function to regulate both signaling and digestion [39, 43, 44].
Inhibition of gastric and pancreatic lipases via orlistat treatment decreases
triglyceride hydrolysis and is able to inhibit absorption of ingested fat by
~30% and contributes to a caloric deficit of approximately 200 calories per
day [45]. As with neurotransmitter reuptake inhibitors, orlistat promotes
weight loss; however, because of side effects the drug is poorly tolerated
by many patients [40].
3) Energy expenditure: The largest contributor to obligatory energy
expenditure is the basal metabolic rate (BMR), which is defined as the
resting energy expenditure at thermoneutrality in the unfed state 48. BMR
includes cellular turnover, repair and basic functions (e.g., maintenance of
ion gradients, transmembrane metabolite transfer), basal synthetic

7

reactions (e.g., RNA, DNA and protein synthesis) and mitochondrial
proton leak. It also includes obligatory thermogenesis (e.g., digestion and
absorption) 48.
Mitochondria are central to the regulation of energy expenditure,
and targeting their activity has been a prospect for obesity therapies for
decades. Perhaps most infamous is the work by Cutting and Tainter

49, 50

,

which showed that 2,4-dinitrophenol (DNP)—a compound found to be
responsible for weight loss in workers of French munitions factories during
World War I—could be used to increase the metabolic rate of patients.
Although the use of DNP led to weight loss as well as improvements in
glucose tolerance in some diabetic patients, results were largely
disastrous: people were “literally cooked to death” due to overdose, as the
systemic uncoupling of mitochondria by DNP resulted in overheating.
Other side effects included rashes, cataracts, and agranulocytosis.
Hence, although the drug was effective for weight loss, it was not deemed
safe by the FDA and was withdrawn from the market in 1938
In

recent

years,

a

more

in-depth

51

.

understanding

of

how

mitochondrial metabolism could be regulated has been sought. Unlike
rudimentary approaches using pharmacological mitochondrial uncouplers,
which have systemic effects, targeting mitochondrial metabolism in
specific tissues may prove more beneficial.

Therapies that mimic

physiological anti-obesogenic effects are likely to prove most effective.
Mitochondria in organs with high energetic need (e.g., the heart) are likely

8

to maintain relatively well-coupled mitochondria, while other organs such
as adipose tissue could afford to be less economical. Overexpression of
uncoupling protein 1 (UCP1), which generates an increase in substrate
utilization and electron transport chain activity, in adipose tissue
skeletal muscle

53

52

or

can prevent diet-induced obesity in mice, suggesting

that uncoupling of oxidative phosphorylation in these two organs is
sufficient

to

regulate

body

composition.

Interestingly,

oxidative

phosphorylation in skeletal muscle is less well-coupled in endurance
athletes compared with sedentary subjects

54

, and this appears to result in

an increase in fatty acid oxidation and a decrease in oxidative stress.
Furthermore, genes encoding fatty acid oxidation are increased in the
skeletal muscle of athletes compared with sedentary subjects

55

,

suggesting a gene profile in athletes that favors fat oxidation rather than
storage 56.
Brown adipose tissue (BAT), which expresses relatively high levels
of UCP1, is an exciting target for therapy. Despite the small amounts in
humans, as little as 50 g of BAT has been estimated to be capable of
utilizing up to 20% of basal caloric needs
BAT mass are prone to obesity
maintain active depots of BAT

57

. Mice with genetically reduced

58

. The recent discovery that adult humans

59, 60

in conjunction with the identification of

UCP2 and UCP3 in the skeletal muscle and other tissues

61, 62

suggests

that enhancement of mitochondrial activity may hold promise for
combatting obesity.

9

Increasing energy expenditure by BAT activation is an anti-obesity
strategy that has recently gained widespread attention and represents an
intriguing new therapeutic approach. However, the finding that adipocytes in
some white adipose tissue depots can be programmed to become similar to BAT
has further invigorated research into understanding the role of adipose tissue in
systemic metabolism.

White adipose tissue is an important regulator of whole-body metabolism
White adipose tissue (WAT) is a complex, essential and highly active
63

metabolic and endocrine organ

. Its utility as the main storage depot for excess

energy from dietary intake has long been recognized

64

, but only recently has its

importance beyond energy storage been fully appreciated. WAT not only
responds to afferent signals from traditional hormone systems and the central
nervous system but it also expresses and secretes factors with important
endocrine functions including cellular signaling, energy metabolism and
inflammatory processes

63, 65

. This network of secreted adipokines signal

changes in the adipose tissue energy status to other metabolic organs that
control fuel consumption and redistribution

66

. In this way, adipose tissue is a

critical regulator of whole-body metabolic homeostasis. The contribution of
adipose tissue to regulating circulating levels of free fatty acids (FFAs), glucose
and insulin is of particular importance

65

and will be discussed in detail in the

following sections.

10

WAT dysfunction in the progression of obesity and diabetes
Chronic energy overload promotes systemic metabolic dysfunction, which
appears to commence at the level of the adipose tissue. Though adipocytes have
a large capacity to synthesize and store triglycerides (TGs) during feeding, after
prolonged periods of nutrient excess their storage and endocrine functions
become compromised

67, 68

. Failure of WAT to store fat appropriately results in

pathological adipocyte hypertrophy, hypoxia and secretion of macrophage
chemoattractants, particularly monocyte chemoattractant protein-1 (MCP-1) 65, 69.
Infiltrating macrophages secrete large amounts of tumor necrosis factor  (TNF)
and other inflammatory cytokines thereby creating a chronic proinflammatory
state in the WAT associated with impaired TG deposition and increased lipolysis
65

. The result is increased circulating TGs and FFAs which can be deposited in

skeletal muscle, liver and β-cells of the pancreas

70, 71

. Elevated FFAs and

ectopic lipid deposition are associated with metabolic dysregulation in peripheral
72-78

tissues of both humans and rodents

. In the liver, infusion of FFAs increases

glucose output and causes insulin resistance

79

. Similarly, skeletal muscle insulin

resistance has been shown to be associated with elevated circulating FFAs and
intramyocellular triglyceride accumulation

80,

81

. Increased hepatic glucose

production and decreased glucose uptake by skeletal muscle (which accounts for
approximately 80% of glucose disposal in the post-prandial state) contributes to
elevated systemic glucose levels

66

. In response, the pancreas releases more

insulin and after prolonged periods of positive energy balance, this leads to

11

hyperinsulinemia

82

. Additionally, chronic exposure to elevated FFAs may result

in β-cell dysfunction 82, 83 a key event in the development of frank T2D.

Proper lipid partitioning is critical in metabolic disease
A critical feature in this model of disease progression is the failure of the
WAT to benignly accommodate excess lipid. When the WAT is unable to
sequester fat, a malignant cascade of events ensues. Studies in rodent models
underscore the importance of fat storage in the adipocyte. These studies show
that increasing adipocyte cell number, and therefore overall adipose tissue mass,
by overexpressing the adipokine adiponectin in severely obese ob/ob mice,
decreased hepatic and muscle fat deposits and normalized metabolic parameters
84

. Therefore, by providing additional adipose depots for fat storage, fat “spillover”

or ectopic deposition in peripheral tissues can be prevented and insulin
resistance and diabetes averted. This is further supported by the observation that
mice almost totally devoid of adipose tissue due to the expression of A-ZIP/F-1
protein in adipocytes, are severely insulin resistant due to defects in insulin
action, particularly insulin receptor substrate (IRS)-1/IRS-2–dependent activation
of PI 3-kinase, in muscle and liver 85. These abnormalities were associated with a
twofold

increase

in

muscle

and

liver

triglyceride

content,

and

upon

transplantation of fat tissue into these mice, triglyceride content in muscle and
liver returned to normal, as did insulin signaling and action

85, 86

. While intensively

studied, the mechanism by which increased lipid in peripheral tissues disrupts
insulin signaling, remains to be fully elucidated

12

87

. What is clear, however, is that

proper partitioning of fat in the WAT rather than in peripheral tissues is crucial for
preserving insulin sensitivity.

WAT mitochondria as therapeutic targets in metabolic disease
While numerous studies have focused on modulating mitochondrial
activity in skeletal muscle and liver to prevent lipid accumulation and maintain
insulin sensitivity, only recently has significant attention been paid to metabolic
intervention at the level of the adipose tissue. Despite adipocytes having a
relatively low mitochondrial abundance, mitochondria are essential for many
adipocyte functions. Previous work has demonstrated that mitochondria play an
important role in the differentiation and the maturation of adipocytes, as
evidenced by a synchronized initiation of adipogenesis and mitochondrial
88

biogenesis

and the promotion of differentiation in response to enhanced

mitochondrial metabolism, biogenesis and reactive oxygen species (ROS)
production

89

. Additionally, adipocyte mitochondria must generate sufficient ATP

to support energy-consuming lipogenic processes, while still maintaining normal
90

cellular activity

. Further, to sustain lipogenesis, mitochondria provide key

intermediates for the synthesis of TGs through the actions of pyruvate
carboxylase

91

.

Reacting

to

cues

from

its

nutritional

and

hormonal

microenvironment, the adipocyte coordinates the appropriate mitochondrial
response to either oxidize incoming FAs and carbohydrates through the
tricarboxylic acid (TCA) cycle and the respiratory chain, or store them as TGs

91

.

In light of this, it has been proposed that ‘FFA recycling in the adipocyte’ (a TG-

13

to-FA cycle) is a crucial sequence of events that determines systemic FFA
concentrations 92.
During obesity and nutrient excess, mitochondrial function in adipocytes is
compromised. Levels of ATP decrease while there is increased accumulation of
NADH

66

, thereby shifting the adipocyte toward lipid storage accompanied by

reduced mitochondrial biogenesis and increased ATP synthesis from glycolysis
91

. Prolonged exposure to nutrient overload only further induces these

mitochondrial alterations and leads to yet more lipid accumulation. Studies in
diabetic mice have shown a decrease in both the number and the function (both
oxidative phosphorylation and β-oxidation) of mitochondria in WAT

93

. Further,

several genes involved in mitochondrial function and oxidative phosphorylation,
as well as PPARα, ERRα, and PGC-1α were downregulated in WAT from high
fat diet-induced obese and db/db mice

94, 95

. Similar changes have been

observed in the WAT of obese, insulin resistant and diabetic patients. In human
WAT, mitochondrial abundance is decreased and genes crucial for mitochondrial
function are downregulated

96

as well. Adipocytes isolated from these patients

had decreased oxygen consumption rates and ATP production

91, 97

. These

findings suggest a clear association between the activity of the mitochondria in
adipose tissue and the pathological remodeling of the tissue that accompanies
obesity.
Targeting the mitochondria of WAT to combat obesity has emerged as a
promising new strategy and has been the subject of increasing scientific scrutiny.
A general idea is to increase mitochondria in WAT, which could promote a higher

14

basal metabolic rate. Several molecular targets have been identified, with PGC1 being of critical importance

98

. PGC-1 is a known regulator of energy

metabolism and of mitochondrial biogenesis

99

and may induce many of the

characteristic brown fat traits in white adipocytes in vitro

98

. Additionally, recent

studies have identified secreted proteins that stimulate brown adipocyte
thermogenesis and recruit brown (or beige) adipocytes to WAT

100

. One such

secreted protein is irisin—a skeletal muscle-derived myokine that enhances
systemic energy expenditure and improves obesity and glucose homeostasis in
mice—via a mechanism, which depends, at least in part, on PGC-1 101.
Interestingly, treatment with the gaseous signaling molecule, nitric oxide
(NO), can induce PGC-1-dependent mitochondrial biogenesis in both mouse
white fat 3T3-L1 adipocytes and brown adipocytes

102, 103

. Importantly, NO-

induced mitochondrial biogenesis leads to the formation of functionally active
mitochondria capable of coupled respiration leading to the generation of ATP
through oxidative phosphorylation

104

. Furthermore, emerging evidence suggests

that changes in vascular function could regulate metabolic homeostasis, and
many studies have shown that NO may play a pivotal role in regulating systemic
metabolism, body composition, and insulin sensitivity. In the sections that follow,
the potential role of NO in regulating metabolism, obesity and insulin resistance
is discussed.

15

Nitric oxide – endogenous formation and
general modes of biological action
Nitric oxide and related nitrogen oxides have emerged as critical
regulators of cell and tissue function

105

. The potency of NO was perhaps first

realized when it was inhaled by Sir Humphrey Davy, who nearly died from the
self-experiment, and after which he vowed to “never design again…so rash an
experiment”

106

. Nearly two centuries later, identification of the cardiovascular

processes controlled by NO led to the Nobel Prize in Physiology or Medicine in
1998. Nevertheless, the pleiotropy of NO continues to unfold, and we are only
now beginning to appreciate the deeper aspects of its impact on metabolism.

Generation of NO
The most common route of NO production is through the action of the
nitric oxide synthase (NOS) family of enzymes

105, 107

. These enzymes catalyze

NADPH- and O2-dependent oxidation of L-arginine to L-citrulline, producing NO
in the process. Such synthesis of NO depends on the availability of cofactors
such as FAD, FMN, tetrahydrobiopterin (BH4), as well as the prosthetic group,
heme 108.
The three NOS isoforms generate NO at different rates

105

. Endothelial

NOS (eNOS) is localized to the vascular endothelium, but has also been found in
neurons, epithelial cells and cardiomyocytes

109

.

It produces relatively low

quantities of NO, and its activity is controlled by Ca 2+ and calmodulin, posttranslational modifications

110, 111

, and physical forces such as shear stress

113

112,

. Neuronal NOS (nNOS) is also a Ca2+/calmodulin-dependent isoform that is
16

activated by agonists of the N-methyl-D-aspartate (NMDA) receptor

113

.

It is

expressed in neurons, skeletal muscle, and epithelial cells. Lastly, inducible NOS
(iNOS), which has the highest capacity to generate NO, is expressed in multiple
cell types in response to inflammatory stimuli

113, 114

. The results of some studies

also suggest the presence of a mitochondria-localized isoform, which could be
important in regulating mitochondrial function

115, 116

; however, the identity of this

isoform remains to be fully established. In addition to post-translational
modifications and substrate and cofactor availability, NOS activity is regulated by
its localization within cells and by interactions with itself and other proteins

113

.

NO could also be produced endogenously from its more oxidized nitrogen
oxide precursor, nitrite. Reduction of nitrite to NO is increased under acidic and
hypoxic conditions, with the reduction occurring enzymatically by heme proteins
such as deoxyhemoglobin or deoxymyoglobin

117

. The therapeutic potential of

dietary or pharmacological nitrite is supported by multiple studies describing
improvements in reperfusion injury following myocardial infarction, in pulmonary
hypertension, and injury after organ transplantation 118.

Biochemical properties of NO
NO is a free radical of rather limited biological reactivity. The endogenous
half-life of NO is in the range of 2 ms to > 2 s and appears to depend primarily on
the availability of metals and oxygen

119

. NO reacts avidly with ferrous (Fe2+) iron

and with other radical species and such reactions form the basis for nearly all of
the biological effects of NO. The highest affinity interactions of NO are with

17

metalloproteins such as soluble guanylate cyclase (sGC), cytochrome c oxidase,
and hemoglobin; NO reacts also with non-heme iron. Reaction of NO with Fe2+
iron results in the formation of a coordinate bond, which is termed a nitrosyl
adduct (i.e., nitrosylation). The presence of free radicals such as superoxide
(O2˙-)

120-123

peroxynitrite

changes the fate of NO because once NO reacts with O2˙- it forms
120, 122, 123

124

and can no longer bind to ferrous heme

. Peroxynitrite

and other reactive species (e.g., NO2) derived from the reaction of NO with O2˙are important in inflammatory responses

123

and can modulate cell signaling

125-

128

, in part by promoting the oxidation and nitration of a broad range of

biomolecules 105.
The NO molecule can also react directly with O2, which itself is a free
radical possessing two unpaired electrons in different π* antibonding orbitals

129

.

The reaction of NO with O2 commonly underlies mechanisms by which Snitrosation or S-oxidation of protein side chains occurs. In addition, NO can react
directly with thiyl radicals, forming a nitroso covalent bond between NO and the
thiol (termed S-nitrosation or S-nitrosylation). Cysteinyl residues of glutathione
and proteins are among the most recognized and studied targets of NO and its
oxidized species [(such as N2O3; collectively called reactive nitrogen species
(RNS)]; reaction of RNS with thiols results in the formation of S-nitrosothiols, Sglutathiolated species, and oxidized cysteinyl residues

130

. Such modifications

can lead to transient changes in enzyme activity, providing redox switches that
can be modulated by addition or removal of the modifications
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131

.

General physiological roles of NO
NO has multiple biological actions and this versatile molecule can regulate
physiology acutely or lead to long-term changes in cell function. The pleiotropic
roles of NO include the regulation of long-term synaptic transmission, learning,
memory,

platelet aggregation,

leukocyte-endothelial interactions,

function, and angiogenesis and arteriogenesis (for review, see

immune

132

). However,

NO is most well known as a potent regulator of blood flow and was originally
termed endothelial-derived relaxing factor (EDRF). The story unfolded from
Furchgott and Zawadzki’s initial discovery that endothelial cells control
acetylcholine-induced relaxation of smooth muscle

133

. A few years later, NO was

identified as the key endothelium-derived molecule promoting vasodilation: NO
synthesized by NOS in the endothelium diffuses into the vessel wall where it
activates sGC in vascular smooth muscle. This leads to an increase in cyclic
GMP (cGMP) levels in the tissue and elicits vessel relaxation

134-140

. However, it

readily became apparent that different isoforms of NOS have different
physiological roles. For example, eNOS and nNOS were found to have distinct
roles in regulating microvascular tone

141

; nNOS activity in the medulla and

hypothalamus is important for systemic regulation of blood pressure

142-145

the nitrergic nerves containing nNOS are responsible for penile erection

; and,

137, 146

.

Overall, NO derived from the integration of eNOS and nNOS activities play key
roles in regulating systemic blood pressure and acutely regulating organ blood
flow, whereas iNOS-derived NO species are most well recognized for their
impact on pathogen killing and inflammatory processes
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120

.

Another key function of NO is the regulation of mitochondrial respiration.
Acutely, NO inhibits respiration by binding and inhibiting cytochrome c oxidase.
Modulation of respiration by NO is dependent on both mitochondrial activity and
the O2 level

147, 148

. In addition, NO directly regulates the binding and release of

oxygen with hemoglobin

149

and is able to increase blood flow at sites of very low

oxygen concentrations

150

Thus, a key function of NO is to modulate O2

.

gradients in cells and tissues by regulating hemoglobin action and by inhibiting
O2 consumption in respiring mitochondria

119

. Chronic exposure to relatively high

levels of NO results in mitochondrial biogenesis

151-153

, which could reprogram a

cell or tissue to have a higher metabolic capacity.

NO bioavailability is diminished in obesity
NO bioavailability is decreased in animal models of obesity
both adult and adolescent humans

156, 157

.

154, 155

and in

Because NO bioavailability is

dependent upon the balance between its generation and degradation, diminished
levels of NO in obese states may be due to decreased expression of NOS,
impairments in NOS activity, decreased NOS substrates or by the reaction of NO
with reactive species (e.g., superoxide) (Fig 2). These are discussed below.

NOS expression changes in obesity
A primary mechanism by which NO bioavailability could be decreased is via
diminished expression of NOS enzymes (Fig. 2A). In particular, lower eNOS
abundance is found in both WAT and skeletal muscle of obese humans and
20

Figure 2. Mechanisms for decreased endothelial-derived NO in obesity and
diabetes. Schematic of changes in NOS or NO: (A) Decreased eNOS
expression commonly occurs in obese and diabetic states. Mechanisms
proposed for diminished expression include TNF-α-mediated destabilization of
eNOS mRNA, which may involve eEF1A1.

High levels of NO may regulate

eNOS abundance through cGMP-mediated or via NF-κB-SNO feedback
regulatory pathways.

A small 27-nt RNA regulates eNOS expression also,

although it is not known whether this mechanism is invoked in obesity or
diabetes.

(B)

Decreased eNOS activity in obesity and diabetes is largely

attributed to insulin resistance, which may be mediated by free fatty acid (FFA)induced activation of TLR2, TLR4, and NF-κB. In addition, activation of PKCβII
may diminish Akt signaling, which causes phosphorylation of eNOS on Ser1177.
Phosphorylation at this site increases NO output by the enzyme. Hyperglycemia
may also lead to increased O-GlcNAcylation of eNOS, which decreases Ser1177
phosphorylation and inhibits its activity. In addition, conditions leading to obesity
promote upregulation of Cav-1, which is a negative regulator of eNOS, and
ceramide accumulation disrupts the eNOS-Akt-HSP90 complex, diminishing
activity of the enzyme. (C) eNOS may also be uncoupled or NO quenched in
obese and diabetic states. Diminished levels of substrates and cofactors, such
as L-arginine or tetrahydrobiopterin (BH4), lead to uncoupling of the enzyme,
which is commonly associated with the presence of eNOS monomers rather than
dimers and can produce superoxide instead of NO. Endogenous inhibitors of
eNOS such as ADMA are also increased in obese conditions and can promote

21

NOS uncoupling. Elevated production of reactive oxygen species such as
superoxide can quench NO and result in its oxidation to highly reactive
peroxynitrite, which damages biomolecules and can oxidize BH 4 to BH2.
Increased levels of BH2 exacerbate NOS uncoupling and superoxide production.
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rodents

158-162

. Factors associated with obesity and diabetes including increased

shear stress, lysophosphatidylcholine, oxidized LDL, insulin and decreased
ability to exercise can also regulate eNOS expression

163-167

. TNF, which is

increased in obesity and implicated in the etiology of insulin resistance
been found to downregulate eNOS expression and abundance

168

, has

161, 169-172

by

173, 174

decreasing the stability of eNOS mRNA

, effectively shortening its half-life

175

. This destabilization of the eNOS message has been linked, at least in part, to

upregulation of elongation factor 1-α1 176.
Acutely, TNF increases eNOS activity
Akt

178

177

, most likely via activation of the PI3K-

and sphingomyelinase/sphingosine-1-phosphate pathways

179, 180

. Such

diametrically opposite acute versus chronic effects of TNF would appear to
suggest the potential existence of negative feedback loops that sense high levels
of NO, leading to downregulation of eNOS. Indeed, NO donors downregulate
eNOS expression both in vitro and in vivo, which may involve cGMP and/or Snitros(yl)ation of NF-κB 181, 182. A small, 27-nt RNA has also been shown to be an
effective feedback regulator of eNOS

183

. Whether such small RNAs or miRNAs

that regulate NOS expression are induced with obesity is currently unclear.
Notable changes in the abundance of other NOS isoforms also occur in
obesity. The iNOS enzyme increases in abundance in pancreatic β-cells
aorta

185

, skeletal muscle

186

, liver

187, 188

, and adipose tissue

189-191

184

,

of obese

rodents. In adipose tissue, the majority of iNOS is derived from infiltrating bone
marrow-derived macrophages that display a proinflammatory phenotype

189-191

.

However, high levels of TNFα were shown to increase iNOS also in adipocytes,
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which appears to downregulate UCP2

192

; hence, this mechanism could

contribute to decreases in WAT energy expenditure. In the ventromedial
hypothalamus, which controls energy intake, diet-induced obesity was associated
with lower numbers of nNOS-expressing cells

193

. In the aorta, however, nNOS

was increased in abundance in mice fed a high fat diet. The induction of nNOS
was demonstrated to be due to leptin stimulation

194

and may partially

compensate for the loss of eNOS-mediated vasodilatory action that typically
occurs in obese, insulin-resistant states.

Changes in eNOS activity in obesity
Beyond changes in expression, the NO-producing activity of eNOS is
diminished in metabolic disease (Fig. 2B). In addition to the required substrates,
calcium, and cofactors, the activity of eNOS is regulated by protein-protein
interactions and by several post-translational modifications

132, 195, 196

. High fat

feeding upregulates caveolin-1, a negative regulator of eNOS
of obese rats

199

.

197, 198

, in the aorta

Furthermore, ceramide (which is increased in obesity

promotes disruption of the eNOS-Akt complex from HSP90

200

)

201

, which increases

eNOS activity by promoting displacement of caveolin-1 from eNOS 202.
Conditions of obesity have profound effects on eNOS phosphorylation. In
particular, eNOS phosphorylation at serine 1177 (S1177; S1176 in mice), which
is critical for increasing NO output from the enzyme
nutrient excess
212

and pigs

213

204-207

or high fat feeding

203

, is diminished in mice by

155, 160, 208, 209

; studies in obese rats

210-

have shown similar results. This eNOS phosphorylation site is

25

regulated by Akt

214

, which is activated by insulin

215

. Insulin stimulation of the

Akt-eNOS pathway could thus be important for regulating post-prandial blood
flow and nutrient disposition to peripheral tissues. Indeed, insulin resistance in
the endothelium is sufficient to diminish NO bioavailability and promote
endothelial dysfunction

216

, and impaired eNOS phosphorylation due to insulin

resistance was shown to be responsible for diminished glucose uptake in the
skeletal muscle of mice subjected to nutrient excess 217.
Reasons for diminished phosphorylation of eNOS under conditions of
nutrient excess and obesity could be due to fatty acid (e.g., palmitate)-mediated
155

induction of insulin resistance
bioavailability in cultured cells
humans

. Elevated free fatty acids lower NO

218

, isolated arteries

219

, animal models

220

and

221, 222

. Insulin resistance due to FFAs may be engendered by activation
208, 218

of Toll-like receptor 4 (TLR4) and NF-κB

or Toll-like receptor 2 (TLR2)

223

.

Other nutrient conditions inherent to diabetes may also be responsible for loss of
S1177-eNOS phosphorylation. For example, hyperglycemia causes O-linked Nacetylglucosamine (O-GlcNAc) modification of eNOS, which diminishes its
activity

224

. Additional mechanisms posited for diminished eNOS phosphorylation

in the context of obesity include a fatty acid-mediated, yet Akt-independent
impairment of eNOS phosphorylation

209

, and PKCβII-mediated diminishment in

Akt and eNOS responsiveness to insulin

210, 212

. How these signaling pathways

integrate to regulate NO production in obesity and diabetes remains to be
addressed.
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Uncoupling of NOS and quenching of NO in metabolic disease
The ability of NOS to produce NO is also dependent on its proper
coupling, which is regulated by multiple cofactors, the ability of the NOS enzyme
to remain in the dimerized form
229

225, 226

, and post-translational modifications 132, 227-

(Fig. 2C). In particular, the cofactor BH4 is critical to NOS activity, and it has

been termed a ‘redox sensor’ because elevations in reactive oxygen and nitrogen
species can result in its depletion
‘health’ of the endothelium

230

. Furthermore, BH4 may reflect the overall

231

. Obese and diabetic states in rodents and human

cells are associated with decreased BH4 and elevated levels of its oxidized form,
BH2

231-235

. This is important because deficiency in BH4 or elevations in BH2 can

uncouple NOS, which results in superoxide production from the enzyme and
increases peroxynitrite generation

227

. Hence, deficiency of BH4 is thought to be

a major regulator of vascular dysfunction that occurs during obesity and in
diabetic states. Indeed, the ratio of BH4 to BH2 is critical in preventing glucoseinduced eNOS uncoupling

236

and replenishment of BH4 pools has proven

effective in multiple pathological scenarios 227, 228, 237-239. Uncoupling of NOS does
not appear to be a factor unique to eNOS, however, as nNOS was shown to be
uncoupled in penile arteries of obese rats, leading to nitrergic dysfunction, which
was restored by increasing BH4 levels 240.
Peroxynitrite may be especially critical in promoting NOS uncoupling. The
3-nitrotyrosine (3-NT) is a typical ‘footprint’ post-translational modification that
helps identify sites at which eNOS uncoupling might have occurred, and it is
worth noting that this modification is observed in abundance in the context of

27

160, 232, 241, 242

obesity and diabetes (e.g.,

). Patients with diabetes had diminished

flow-mediated dilation of coronary arterioles and increased 3-NT protein adducts
that colocalized with caveolae, demonstrating a dysfunction of the endothelium
associated with elevated peroxynitrite production

243

. Interestingly, endothelial

dysfunction in diabetic patients was rescued by sepiapterin supplementation

243

,

inferring that peroxynitrite may disrupt eNOS function not only by caveolar
disruption, but by depleting BH4. This would be consistent with multiple studies
showing that elevated levels of reactive species (in addition to peroxynitrite, such
as superoxide produced from NADPH oxidase) promote eNOS uncoupling

244-248

.

Nevertheless, the specific contribution of peroxynitrite and other reactive species
to endothelial function is still unclear. Some studies suggest that rather than
contributing to the uncoupling of eNOS, superoxide derived from NADPH oxidase
activates the enzyme

249

. Hence, inhibited eNOS function perceived under

conditions of oxidative stress could be due in part to the quenching of NO and
not to uncoupling of the enzyme per se. While this would be consistent with the
near diffusion-limited reaction rate of NO with superoxide (which is reported to be
as high as 1.9 × 1010 M-1 s-1) 250, the evidence for a deleterious role of uncoupled
NOS should not be underestimated, and multiple other factors beyond BH 4
depletion, such as asymmetric dimethyl arginine (ADMA) levels, insufficient Larginine levels or glutathio(ny)lation of the eNOS enzyme, can promote eNOS
uncoupling and endothelial dysfunction

132, 251-254

. That levels of ADMA are

positively correlated with insulin resistance and diabetes, and that arginine
supplementation overcomes this competitive inhibition

28

255

further suggests that

eNOS uncoupling or inhibition are major contributors to the development of
metabolic diseases associated with obesity.
Despite these findings, it is unclear whether obesity itself decreases NO
availability. The fact that obesity in humans is associated with decreased blood
flow in response to methacholine
acetylcholine

258

, shear stress

256

, bradykinin

259

, and insulin

260, 261

257, 258

, substance P and

appears to suggest that the

obese condition is somehow linked causally with diminished vascular NO
bioavailability. Several studies showing similar results lend credence to this
hypothesis

158, 262-273

. However, the question remains: Is loss of NO production

somehow due to excess adiposity, or is its etiology derived from those conditions
commonly associated with obesity? Interestingly, endothelial dysfunction was
found to occur in morbidly obese humans only in the presence of insulin
resistance 274. And, severely obese humans, in the absence of insulin resistance,
showed better flow-mediated dilation compared with normal and obese insulinsensitive subjects

275

. Furthermore, capillary recruitment has been shown to be

higher in overweight compared with lean individuals

276

. This suggests that the

maintenance of a metabolically benign form of obesity is possible and that either
insulin resistance or conditions directly linked with the insulin resistant phenotype
(e.g., dyslipidemia, inflammation, hyperglycemia) are to blame for loss of NO
bioavailability during obesity.

Collectively, these findings raise multiple

questions: What determines how the metabolically benign versus harmful forms
of obesity develop?; How does NO affect obesity and insulin resistance?; What is
the relevance of changes in NOS isoform abundance, (some of which go in

29

diametrically opposite directions (e.g., eNOS vs. iNOS)), in the development of
metabolic disease?; and, how does NO regulate tissue-specific metabolic
pathways?

30

Project Objective
Extensive evidence shows that obesity is a robust risk factor for the development
of T2D, yet the mechanisms by which obesity increases the risk of T2D remain
unclear. Recent studies suggest that endothelial dysfunction, characterized by a
decrease in nitric oxide (NO) production, is pivotal in the progression of metabolic
disease. The endothelium is a central regulator of insulin sensitivity and is the
first tissue to become insulin resistant. In addition, it has been reported that
deletion of eNOS is associated with adiposity, insulin resistance and impaired
fatty acid oxidation. Nevertheless, the role of eNOS in regulating metabolism is
not well understood. The overall goal of my work is to understand how NO
regulates metabolism. We propose that during nutrient excess decreased
vascular-derived NO bioavailability is a critical step that leads to the development
of metabolic dysregulation. Specifically, we hypothesize that an increase in
NO derived from eNOS prevents diet-induced obesity by promoting
adipose tissue browning and increasing systemic metabolism. To determine
effects of nutrient excess on tissues critical to obesity-related insulin resistance,
we examined nutrient excess-induced metabolic changes occurring in adipose
tissue. As discussed in Chapter II, we found changes consistent with
mitochondrial remodeling and loss of mitochondrial bioenergetic capacity in
adipose tissue. Further we show that obesity induces profound decreases in
eNOS abundance. To assess the significance of eNOS downregulation, we
investigated whether increasing eNOS expression was sufficient to prevent
obesity-related metabolic consequences (Chapter III, Aim I). After studying the
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anti-obesogenic effects of eNOS, we examined how overexpression of eNOS
affects systemic metabolism (Chapter IV, Aim II). Our findings reveal an
important role of NO in regulating metabolism and suggest that increasing NO
could prevent diet-induced obesity. In addition, our findings support the view that,
while obesity and insulin resistance are closely associated they remain distinctly
separate consequences of nutrient excess.
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CHAPTER II
METABOLIC REMODELING OF WHITE ADIPOSE TISSUE IN OBESIT.

Introduction
The increasing prevalence of obesity is a principal health concern
worldwide. In 2008, approximately 1.5 billion adults aged 20 years or older were
overweight, and 10% were obese 1. In the US, more than one-third of the adult
population is currently obese (BMI >30), and 68% have a BMI>25

277

; these

numbers are expected to increase by more than 50% by the year 2025 7. These
statistics are cause for alarm. Obesity is a powerful predictor of insulin resistance
4

and a major risk factor for several common medical conditions, including type 2

diabetes (T2D), cardiovascular disease, non-alcoholic fatty liver and gallstones,
Alzheimer’s disease, and some cancers 278.
While lack of exercise is an undeniable risk factor for weight gain

278-280

,

excessive caloric intake appears to be one of the key factors fueling the obesity
epidemic. In the past three decades, the average consumption of calories in the
US has increased by at least 200 kcal/d per person, which is partly attributable to
an increase in the intake of energy-dense foods

8-10, 281

. Such poor dietary habits

negatively affect metabolic homeostasis, which could not only promote obesity,
but the development of obesity-related co-morbidities as well. Despite the
33

simplicity of the apparent remedy (i.e., decreasing caloric intake), treatment of
obesity remains a challenging crisis facing the health care system. Losing weight
via caloric restriction faces multiple conceptual challenges: these include an
evolutionarily engendered guard against starvation and low fat mass
propensity to increase caloric efficiency during dieting

32, 33

.

7, 31

and a

While several

approaches to combat obesity have been approved for clinical use, including
medications that reduce caloric intake or absorption and bariatric surgery, these
approaches in many cases show marginal long-term efficacy or have
unacceptable or overtly dangerous side effects 7.

Thus, recent strategies to

modulate obesity have begun to target tissues that naturally regulate energy
metabolism.
Increasing energy expenditure by modulating adipose tissue activity has
become an especially attractive target for therapy. Guided by the fact that adult
humans maintain small depots of brown fat capable of burning significant
amounts of calorific energy

57

, multiple studies focused on the physiological and

molecular mechanisms regulating the thermogenic capacity of adipose tissue.
These studies show that adaptive thermogenesis in brown fat can be a powerful
regulator of systemic energy metabolism. However, the relatively small amount
of brown adipose (less than 0.4% of body weight) compared with white adipose
tissue (WAT; which can comprise 40% or more of the body weight of an obese
human) suggests that WAT may be a more tangible target. Interestingly, white
adipose depots, which typically function to esterify free fatty acids (FFA) and
store excess lipids, have the capacity to develop brown adipose-like tissue
34

capable of modulating systemic metabolism and preventing obesity and insulin
resistance 282.
While the phenomenon of adipose “browning” is an exciting area of
research, there is also considerable interest in understanding the metabolic
changes that occur in WAT with obesity. It has become increasingly clear that
conditions of nutrient excess promote a “whitening” of adipose tissue
characterized by decreases in mitochondrial abundance

93, 283, 284

. Hence, while

promoting “browning” is one way to positively modulate metabolism, decreasing
adipose tissue “whitening” could in principle prevent the dysregulation of
systemic metabolism caused by obesity. Indeed, the therapeutic actions of
thiazolidinediones such as rosiglitazone and pioglitazone have been suggested
to be due to their ability to prevent loss of mitochondria or increase mitochondrial
function in WAT

284, 285

. Nevertheless, the metabolic changes occurring during

adipose tissue whitening have not been well-characterized, in part because these
metabolic changes have been difficult to dissect from other sequelae of obesity
such as adipose tissue inflammation.
In this study, we examined both the systemic and WAT-specific changes
in metabolism in a common model of diet-induced obesity—the C57BL/6J mouse
fed a high fat diet (60% kcal from fat). Our data indicate that mitochondrial
remodeling, leading to decreases in mitochondrial oxidative phosphorylation and
substrate oxidation, precedes the infiltration of inflammatory cells such as
macrophages.

The changes apparently precede overt loss of mitochondrial

mass and coincide with decreases in PGC1α and dysregulation of lipid and
35

amino acid metabolism.

In addition, we find ultrastructural and biochemical

changes consistent with autophagy and mitochondrial remodeling, the onset of
which also appears to precede the infiltration of macrophages. These findings
have important implications for our understanding of the effects of obesity on
adipose tissue metabolism and suggest that inhibiting the metabolic changes that
contribute to adipose whitening could form the basis for novel therapies to
combat metabolic disease.

Experimental Procedures
Animal studies: All procedures were approved by the University of Louisville
Institutional Animal Care and Use Committee. C57BL/6J (wild-type; WT) mice
were purchased from The Jackson Laboratory (Bar Harbor, ME). At 8 weeks of
age, male mice were placed on either a 10% low fat diet (LFD; Research Diets,
Inc., #D12450B) or a 60% high fat diet (HFD; Research Diets Inc., #D12492) for
6 or 12 weeks. Water and diet were provided ad libitum. Body weights were
recorded weekly.

Metabolic phenotyping: Body composition was measured by dual-energy X-ray
absorptiometry using a mouse densitometer (PIXImus2; Lunar, Madison, WI),
and whole body energy expenditure, respiratory exchange ratio, food
consumption, and locomotion, ambulatory and fine movements were measured
using a physiological/metabolic cage system (TSE PhenoMaster System, Bad
36

Homberg, Germany)

286

. Glucose and insulin tolerance tests and plasma levels

of insulin were measured as described in Sansbury et al

286

.

Adipocyte size measurements: Adipose tissue was excised at the time of
euthanasia, and wet weight was recorded. All adipose tissue was either snapfrozen at –80°C or fixed in 10% formalin (Leica), paraffin embedded, and
sectioned. Sections were stained in hematoxylin and eosin. Adipocyte crosssectional area and size distribution was determined using Nikon Elements.
Adipose tissue sections were assessed for crown-like structures as described
previously 287.

Adipose tissue metabolite profiling: WAT from the epididymal fat pads of mice
fed a LFD or HFD for 6 weeks were used for these analyses. Prior to tissue
collection, mice were fasted for 16 h. After euthanasia, the adipose tissue was
removed and immediately snap-frozen in liquid nitrogen. Relative metabolite
abundance was then measured by GC/MS or LC/MS as described before

286

.

Metabolites with missing values were imputed by replacing missing values with
half of the minimum positive value in the original data. Metabolites with greater
than 57% of values missing were omitted from the analysis. After a generalized
logarithm transformation, data were autoscaled, i.e., mean-centered and divided
by the standard deviation of each variable. This step was performed to transform
the intensity values so that the distribution was more Gaussian. T-test statistical
37

comparisons were then performed. Univariate (e.g., volcano plots), multivariate
(e.g., PLS-DA), and cluster (heatmap and dendogram) analyses were then
performed. Most analyses were performed using Metaboanalyst 2.0 software
(http://www.metaboanalyst.ca/)

288

; z-score plots were constructed in GraphPad

5.0 software using data derived from volcano plot analysis.

Adipose tissue bioenergetic measurements: The oxygen consumption rate
(OCR) of intact WAT explants was measured using a Seahorse XF24 analyzer
(Seahorse Bioscience, Billerica, MA) as described previously

286

. At least two

replicates from each animal were used for the assay. After baseline
measurements, the maximal OCR was measured by exposing the explants to
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (10 µM).

The

non-mitochondrial OCR was measured following injection of antimycin A (25 μM)
and rotenone (5 μM).

Citrate synthase acitivity assay: Citrate synthase activity was measured in 100
mM Tris-HCl, pH 8.0, containing 1 mM EDTA, 1 mM 5', 5'-Dithiobis 2nitrobenzoic acid (DTNB), 10 mM acetyl-CoA. The reaction was initiated by
addition of 10 mM oxaloacetate. Cuvettes were warmed to 37°C, and upon
addition of 10 μg of protein from WAT lysates, absorbance at 420 nm was
measured for 10 min. Activity was expressed as nmoles/min/μg protein.
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Expression analyses: For quantitative RT-PCR, RNA was extracted from
tissues using the RNeasy lipid tissue kit (Qiagen), followed by cDNA synthesis.
Real-time PCR amplification was performed with SYBR Green qPCR Master Mix
(SA Biosciences) using a 7900HT Fast Real-Time PCR System (Applied
Biosystems) and commercially available primers for il1, tnfa, il6, arg1, il10, ym1,
hif1a, emr1, pgc1a, cytc, sirt1, sirt3, pdk4, cpt1a, cpt1b, cox7a1, hprt, and idh3a
(SA Biosciences). Relative expression was determined by the 2 −ΔΔCT method. M1
macrophages in WAT were measured by flow cytometry using well-validated
surface markers as shown previously 287.
To measure protein abundance, WAT homogenates were prepared
exactly as described in Horrillo et al 289. Equal amounts of protein were separated
by SDS-PAGE, electroblotted to PVDF membranes, and probed using primary
antibodies according to the manufacturers’ protocol. The antibodies used were:
ALDH2 (Abcam), Sirt3 (Cell Signaling), MitoProfile® Total OXPHOS Rodent WB
Antibody Cocktail (Mitosciences), COX4I1 (Cell Signaling), GAPDH (Cell
Signaling), Parkin (Abcam), Pink1 (Cell Signaling), p62 (Cell Signaling), LC3
(Cell Signaling), protein-ubiquitin (Cell Signaling) and α-tubulin (Cell Signaling).
Fluorescent or HRP-linked secondary antibodies (Invitrogen) were used for
detection and visualized with a Typhoon 9400 variable mode imager (GE
Healthcare). Band intensity was determined using Image Quant TL ® software.
Relative

mitochondrial

DNA

(mtDNA)

measurements:

Mitochondrial

abundance in adipose tissue was estimated by measuring the mtDNA
abundance relative to nDNA, essentially as described previously
39

290

. Total DNA

was isolated from WAT using a QIAamp DNA Mini Kit (Qiagen). Aliquots of 25
mg tissue were homogenized followed by overnight digestion in Proteinase K at
55°C. Following isolation, relative amounts of mtDNA and nuclear DNA (nDNA)
were compared using quantitative RT PCR. In each assay 2 ng of DNA was
used with specific primers for cytochrome b (mtDNA) and β-actin (nDNA).
Sequences

for

the

primer

sets

used

were:

TTGGGTTGTTTGATCCTGTTTCG-3’

cytochrome
and

CTTCGCTTTCCACTTCATCTTACC-3’;

β

b,

5’5’-

-actin,

5’-

CAGGATGCCTCTCTTGCTCT-3’ and 5’-CGTCTTCCCCTCCATCGT-3’.

Electron microscopy: Adipose tissues were fixed with 3% glutaraldehyde in 0.1
M sodium phosphate buffer (pH 7.4) for 4 h at room temperature (25 °C). Tissues
were then post-fixed with 1% osmium tetroxide for 1 h, dehydrated, embedded in
Embed-812 plastic (Electron Microscopy Sciences). Ultrathin (50-70 nm) sections
were stained with uranyl acetate and Reynolds lead citrate, and electron
micrographs were taken using a Philips CM10 transmission electron microscope
operating at 80 kV.

Statistical analyses: Data are mean ± SEM. Unpaired Student’s t test was
used for direct comparisons. Statistical analyses for metabolomic datasets were
performed using Metaboanalyst 2.0 software. A p value <0.05 was considered
significant.
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Results
High fat diet leads to increased adiposity and altered systemic metabolism.
Wild-type C57BL/6J mice were placed on a LFD or HFD for 6 weeks. Significant
weight gain occurred as early as 1 week on HFD, and the change in total body
mass was nearly 10 g by 6 weeks on the diet (Fig. 3A). Food and water intake
were not significantly different between groups (Fig. 3B,C). Dexascan analysis
showed a 2-fold increase in fat mass and a concomitant decrease in lean mass
in HF-fed mice (Fig. 3D,E). These results are typical of this commonly utilized
model of diet-induced obesity, e.g., see 155, 286.
To determine how diet affects systemic metabolism, mice fed either LFD or HFD
for 6 weeks were placed in metabolic chambers, and their oxygen consumption
(VO2), carbon dioxide production (VCO2), and physical activity were measured.
As shown in Fig. 3F and G, average VO2 and VCO2 values decreased in HF-fed
mice compared with mice fed a LFD. The respiratory exchange ratio (RER) was
also decreased in mice fed a HFD compared with mice fed LFD (Fig. 3H).
Physical activity, measured by total beam breaks (Fig. 3I), ambulatory counts
(Fig. 3J), and fine movements (Fig. 3K), was not significantly different between
groups, although the group fed a HFD appeared to show a trend toward
decreased physical movement. Similar to previous studies

286

, mice fed a HFD

also demonstrated worsened glucose and insulin tolerance (Fig. 4) as well as a
significant increase in plasma insulin levels (WT LFD, 151±71 pg/ml vs. WT
HFD, 2690±593 pg/ml, n = 3 per group, p<0.05).
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Figure 3. Effects of high fat diet on weight gain, adiposity and systemic
metabolism. Male WT C57BL/6J mice were fed a low fat diet (LFD, 10% kcal
fat) or high fat diet (HFD, 60% kcal fat) for 6 weeks and the following
measurements were recorded: (A) mouse weights during 6 weeks of feeding, n =
20 per group; (B) food intake, n = 7 per group; (C) water intake, n = 7 per group;
(D) representative DexaScan images; (E) percentages of lean mass and body
fat, n = 10 per group; and (F) average oxygen consumption (VO2); (G) average
carbon dioxide production (VCO2); (H) respiratory exchange ratio (RER); (I) total
activity level; (J) ambulatory counts; and (K) fine movements. n = 7 per group;
*p<0.05 vs. LFD.
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Figure 4. Glucose and insulin tolerance in mice fed low fat or high fat diets.
After 6 weeks of a low fat (LFD) or high fat diet (HFD), glucose tolerance and
insulin sensitivity were examined: (A) Glucose tolerance test (GTT); (B) GTT
area under the curve (AUC); (C) insulin tolerance test (ITT) shown as % of
baseline; and (D) ITT AUC. n = 7 per group; *p<0.05, **p<0.01 vs. LFD.
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Macrophage infiltration does not occur until after 6 weeks of HFD. To
measure the metabolic effects of obesity on adipocytes in the intact adipose
organ, effects of inflammatory cells such as macrophages must first be ruled out
or otherwise delineated. To examine effects of HFD on macrophage infiltration,
we placed mice on LFD or HFD for 6 and 12 weeks and measured adipocyte
size, crown-like structures indicative of macrophage infiltration, and the
expression of inflammatory genes. As shown in Fig. 5A–C, mice fed a HFD for 6
and 12 weeks showed a 3–4-fold increase in adipocyte size when compared with
LFD controls. While sections of WAT derived from mice fed a HFD for 12 weeks
showed obvious increases in crown-like structures, WAT from mice fed HFD for 6
weeks showed minimal changes in such structures. This suggested that with 6
weeks of HFD, there was minimal macrophage accumulation.

Indeed, the

expression of emr1—a marker of macrophages—as well as that of other
inflammatory genes was not changed with 6 weeks of HFD, and hypoxia was not
evident as measured by expression of Hif1a (Fig. 5D). Moreover, the abundance
of M1 macrophages in adipose tissue stromal vascular fractions was not different
between mice fed the different diets (F4/80+/CD11c+/CD301- cells as F4/80+
cells: LFD 37.4±3.5; HFD, 45.9±1.8; n = 9–10 per group, p>0.05.). Most likely,
the modest, insignificant increase in Tnfa is due to adipocytes, which have been
shown to produce TNF-α 291, 292. Collectively, these data show that after 6 weeks
of HFD, there is an increase in adipocyte size without significant changes in
infiltrating inflammatory cells.
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Figure 5. Effect of HFD on adipose tissue expansion and inflammation.
Morphological and molecular changes in adipose tissues: (A) Representative
hematoxylin and eosin stains of epididymal adipose tissue of mice fed a LFD or
HFD for 6 or 12 weeks; (B) average size of adipocytes; (C) adipocyte size
distribution; and (D) qRT-PCR analyses of markers of inflammation in adipose
tissues from mice fed a LFD or HFD for 6 weeks. CLS, crown-like structure; n =
4-5 per group; *p<0.05 vs. indicated groups.

47

48

Obesity alters the metabolite profile of adipose tissue. To examine the effect
of obesity on adipose tissue metabolism, epididymal WAT from mice fed a LFD
or HFD for 6 weeks was subjected to unbiased metabolomic analysis.

The

relative concentrations of adipose metabolites were measured by mass
spectrometry and queried against the Metabolon reference library. Partial least
squares-discriminant analysis (PLS-DA) showed that the LFD samples clearly
separate from HFD samples (Fig. 6A), and cluster analysis showed that the
abundance of most metabolites was decreased in the HFD group compared with
the LFD group (Fig. 6B). Out of the 191 metabolites measured, 82 were found to
be significantly different (p<0.05) in the WAT of mice fed a HFD compared with
that of adipose from mice fed a LFD. Volcano plot analysis showed that the
levels of 79 metabolites decreased significantly and only 3 metabolites increased
significantly with HF feeding (Fig. 6C and Table 1). To examine and visualize the
data in the biological context of metabolic pathways, metabolites that were
statistically different in each group were analyzed using the MetPA tool of
Metaboanalyst 2.0 software.

Pathways were calculated as the sum of the

importance measures of the matched metabolites normalized by the sum of the
importance measures of all metabolites in each pathway

288

. As shown in Fig.

6D, the highest pathway impact values were related with branched chain amino
acid (BCAA) metabolism (i.e., Val, Leu, and Ile metabolism) and Phe, Tyr and
Trp metabolism. Significant changes were also observed in His metabolism as
well as Gly and Ser metabolism. Glycerophospholipid metabolism showed the
most significant change with HF feeding. To further delineate changes in
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Figure 6. Metabolomic analyses of adipose tissue. Metabolomic analyses of
epididymal adipose tissue metabolites from WT mice fed a LFD or HFD for 6
weeks: (A) Multivariate analysis: partial least squares-discriminant analysis (PLSDA); (B) Hierarchial clustering: Heatmap and dendogram; (C) Univariate
analysis: Volcano plot of metabolites. Those metabolites that significantly
increased are in the quadrant shaded red and those that significantly decreased
are shaded green (p<0.05, t-test). A list of these metabolites can be found in
Table 1; (D) Metabolites found to be significantly different were subjected to
pathway impact analysis using Metaboanalyst MetPA and the Mus musculus
pathway library. Fisher’s exact test was used for overrepresentation analysis,
and relative betweenness centrality was used for pathway topology analysis. n =
14 animals: 7 WT LFD and 7 WT HFD
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Table 1. List of adipose tissue metabolites that changed significantly in
high fat-fed mice.
Fold
change
0.54948
0.45023
0.25885
0.44838
0.34372
0.35614
0.56087
0.55922
0.41779
0.49838
0.5918
0.32145
0.46664
0.48746
0.63104
0.37579
0.46937
0.33055
0.49615
0.66176
0.49975
0.50099
0.26069
0.6417
1.5377
0.75187
0.7317
0.53405
0.49012
0.73299
0.59509
0.38721
0.37705
0.55648
0.54575
0.20024
0.38909
0.60096
0.51634
0.50143
0.75975

Metabolite
threonine
leucine
ergothioneine
tyrosine
valine
phenylalanine
phosphoethanolamine
proline
pantothenate
lysine
xanthine
1,5-anhydroglucitol (1,5-AG)
isoleucine
betaine
asparagine
mead acid (20:3n9)
flavin adenine dinucleotide (FAD)
3-dehydrocarnitine
tryptophan
carnitine
methionine
serine
histamine
arginine
glycerophosphoethanolamine
glutamine
cholesterol
C-glycosyltryptophan
cis-vaccenate (18:1n7)
citrulline
phosphate
urea
17-methylstearate
nicotinamide
hydroxyisovaleroyl carnitine
mannose-6-phosphate
histidine
choline
palmitoleate (16:1n7)
glycerol
taurine
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p value
2.03E-08
6.26E-08
7.34E-07
2.05E-06
3.68E-06
4.73E-06
5.51E-06
6.39E-06
1.70E-05
2.14E-05
3.02E-05
3.73E-05
4.36E-05
4.84E-05
7.38E-05
7.54E-05
7.75E-05
8.10E-05
9.37E-05
0.000107
0.000175
0.000188
0.000204
0.000208
0.000292
0.000295
0.000403
0.00041
0.000438
0.000454
0.000459
0.000489
0.000566
0.000601
0.000634
0.001153
0.001154
0.001218
0.001386
0.001522
0.001556

FDR
3.57E-06
5.51E-06
4.31E-05
9.03E-05
0.00013
0.000139
0.000139
0.000141
0.000333
0.000376
0.000484
0.000547
0.000591
0.000608
0.000792
0.000792
0.000792
0.000792
0.000868
0.00094
0.001466
0.001502
0.001523
0.001523
0.001997
0.001997
0.002579
0.002579
0.002608
0.002608
0.002608
0.002689
0.00302
0.003114
0.00319
0.00549
0.00549
0.005641
0.006253
0.00668
0.00668

glucose-6-phosphate (G6P)
0.29197
1-stearoylglycerophosphoinositol
0.49031
uracil
0.44141
hypoxanthine
0.35895
isobutyrylcarnitine
0.4573
isopalmitic acid
0.28706
uridine
0.53462
scyllo-inositol
0.39204
S-adenosylhomocysteine (SAH)
0.49132
1-oleoylglycerophosphoethanolamine
0.47672
1-palmitoylglycerophosphoethanolamine
0.58479
glycerol 3-phosphate (G3P)
0.59732
1-palmitoylglycerophosphoinositol
0.66829
nonadecanoate (19:0)
0.47985
cysteine
0.5292
eicosenoate (20:1n9 or 11)
0.40267
10-nonadecenoate (19:1n9)
0.45235
cysteine-glutathione disulfide
0.5291
palmitoyl sphingomyelin
0.60227
choline phosphate
0.74957
N-acetylglucosamine 6-phosphate
0.39909
1-arachidonoylglycerophosphoinositol
0.48542
2-hydroxyglutarate
0.39816
inosine
0.45019
glycerol 2-phosphate
0.39934
cytidine
0.59371
stearoyl sphingomyelin
1.5942
urate
0.49862
1-arachidonoylglycerophosphoethanolamine
0.57421
1-palmitoleoylglycerophosphoethanolamine
0.26907
stearidonate (18:4n3)
0.65008
lactate
0.63047
alpha-tocopherol
0.33155
oleate (18:1n9)
0.6828
2-methylbutyroylcarnitine
0.42844
palmitate (16:0)
0.71324
isovalerylcarnitine
0.39518
guanosine
0.52357
succinate
1.3363
adenosine
0.73547
Wild-type (WT) mice were fed a low fat or high fat

0.001647
0.002247
0.002558
0.002619
0.002703
0.002733
0.002775
0.00328
0.003745
0.004631
0.004838
0.005149
0.005556
0.006228
0.007339
0.00756
0.00767
0.008825
0.009257
0.010514
0.012184
0.012459
0.013183
0.013616
0.014415
0.015663
0.015695
0.020514
0.021629
0.023675
0.024231
0.025519
0.025663
0.030736
0.036105
0.03874
0.040257
0.044904
0.047935
0.048468
diet (LFD

0.006899
0.009195
0.010175
0.010175
0.010175
0.010175
0.010175
0.011781
0.013182
0.015981
0.016374
0.017099
0.01811
0.01993
0.023067
0.023275
0.023275
0.026327
0.027153
0.030335
0.034588
0.034806
0.036253
0.036867
0.038439
0.040621
0.040621
0.052327
0.054382
0.058687
0.05923
0.061036
0.061036
0.072127
0.083611
0.088549
0.090836
0.10004
0.10531
0.10531
or HFD,

respectively) for 6 weeks. Epididymal adipose tissue was then subjected to LC
or GC mass spectrometric analysis. Those metabolites found to be significantly
different by t-test are listed above. n = 7 mice per group.
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metabolites, we examined those metabolites that were either significantly
elevated or those that were decreased in abundance by more than 60%. As
shown in Fig. 7, stearoyl sphingomyelin, glycerophosphoethanolamine, and
succinate were the only metabolites that increased in abundance in WAT derived
from HF-fed mice.

The majority of metabolites that decreased by >60%

belonged to the lipid and amino acid superfamilies.

The effect of obesity on mitochondrial oxygen consumption and
mitochondrial remodeling in WAT explants. The increase in succinate found
in our metabolomic analyses suggested that HFD may alter adipose tissue
bioenergetics. Importantly, these changes occurred in the absence of
inflammatory cell infiltration (see Fig. 5), which could otherwise confound
adipocyte-specific changes in metabolism. To determine how obesity affects
adipose tissue mitochondrial function, WAT explants from mice fed a LFD or
HFD were subjected to extracellular flux analysis. As shown in Fig. 8A and B,
the apparent basal mitochondrial oxygen consumption rate of adipose tissue
derived from mice fed a LFD was >2-fold higher when compared with adipose
explants derived from HF-fed mice (p<0.05); however, statistical significance in
OCR between groups was lost upon exposure of explants to FCCP (Fig. 8C).
This appeared to be largely due to an enhanced FCCP response in WAT
explants from obese mice. As shown in Fig. 8D, explants derived from mice fed
a HFD responded more strongly to FCCP. No significant difference in the
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Figure 7. Z-score plot analysis of metabolite changes in adipose tissue
from high fat fed mice. Mice were fed a LFD or HFD for 6 weeks. Data are
shown as standard deviations from the mean of LFD. Only the metabolites that
increased significantly and those that decreased by >60% are shown. Each point
represents one metabolite in one sample. n = 7 per group.
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extracellular acidification rate (ECAR, a measure of the coupling between
glycolysis and glucose oxidation) was observed.
Although citrate synthase activity was decreased by more than 50% in
WAT derived from these mice (Fig. 8E), which suggested a decrease in
mitochondrial abundance, relative abundance of mtDNA, as assessed by qPCR
of mtDNA and nDNA, was not changed after 6 weeks of diet (Fig. 8F). From our
protein determination measurements, we calculated that the yield of protein per
wet weight is diminished by 43% in adipose tissue from high fat-fed mice (µg
protein/mg wet weight: 6 wk LFD, 10.86±1.70; 6 wk HFD, 6.21±1.28; n = 10–12
per group). Applying this information to our data would then shift the OCR curves
to levels near those observed in explants from low fat-fed mice; which suggested
no overall change in oxygen consumption per mitochondrion. However, the
expression of cox7a1, a subunit in the electron transport chain per mg protein,
was increased more than 2-fold in adipose tissue from mice fed a HFD, whereas
pgc1a, sirt3, and pdk4 expression were decreased (Fig. 8G) which indicated
mitochondrial remodeling with preserved function.
To examine how WAT mitochondria change with obesity, we assessed the
relative abundance of several mitochondrial complex proteins as well as
mitochondrial matrix proteins. Although no changes in mitochondrial protein
abundance were observed at 6 weeks of HFD, the protein levels of NDUFB8,
SDHB, and COX4I1—subunits of complexes I, II, and IV, respectively—were
diminished significantly by 12 weeks of HFD (Fig. 9A–D). The matrix proteins
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Figure 8. Obesity-related energetic changes in white adipose tissue.
Metabolic analysis of adipose tissue from mice fed a LFD or HFD for 6 weeks:
(A) Extracellular flux analysis: After three basal oxygen consumption rate (OCR)
measurements, FCCP (10 µM) was injected, followed by injection of antimycin A
(AA, 25 μM) and rotenone (Rot, 5 μM). The apparent contribution of the nonmitochondrial OCR to the total OCR is indicated by the gray box. (B) Apparent
basal mitochondrial OCR: The stabilized non-mitochondrial OCR achieved after
AA+Rot treatment was subtracted from the basal OCR to calculate the rate of
mitochondrial oxygen utilization in each explant; (C) FCCP-stimulated OCR: The
FCCP-stimulated OCR was calculated by subtracting the non-mitochondrial OCR
from maximal rate achieved after FCCP addition; (D) FCCP response: the FCCP
response in each explant was calculated using the equation: (OCR MAX/OCRBASAL)
× 100; n = 10 mice per group; (E) citrate synthase activity, n = 3-6 mice per
group; (F) Relative mtDNA content, n = 6 per group; and (G) expression of
metabolic genes, n = 4 mice per group. *p<0.05 vs. LFD group.
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Figure 9. Obesity-related changes in mitochondrial protein abundance in
white adipose tissue. Analysis of adipose tissue from mice fed a LFD or HFD
for 6 or 12 weeks: (A) Representative Western blots of mitochondrial matrix
proteins and respiratory chain subunits; (B) Quantification of ALDH2; (C)
Quantification of Sirt3; (D) Quantification of respiratory subunit abundance. All
blots were normalized to ATP5A, which showed no change in abundance in any
group. n = 4 per group; *p<0.05 vs. 6 wk LFD, #p<0.05 vs 12 wk LFD.
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ALDH2 and Sirt3 showed similar trends, with ALDH2 decreasing significantly by
12 weeks of HFD.

Assessment of adipose tissue ultrastructure. To examine in greater detail the
subcellular changes that occur in adipose tissue of nutrient-stressed animals, we
examined adipocyte ultrastructure using electron microscopy. As shown in Fig
8A, adipose tissue from mice fed a LFD showed mitochondria with three distinct
morphologies: a round morphology of small size that was located near the
nucleus (Fig. 10A-i,ii), a typical elongated shape up to ~0.7 μm in length located
in small protrusions along the adipocyte cell membrane (Fig. 10A-iii), and
extremely long mitochondria (up to 5 μm and above) that were located in
juxtaposition to the fat locule (Fig. 10A-iv). In adipocytes derived from HF-fed
mice, autophagosomes—defined by a double-membrane and comprising
cytoplasmic constituents—were found next to mitochondria (Fig. 10B-i), and
large

vacuoles

of

electron-dense

material

were

present

adjacent

to

autophagosomes (Fig. 10B-ii,iii). In addition, many mitochondria in adipose
tissues from HF-fed mice appeared to be undergoing fission (Fig. 10B-iv,v).

Effects of HFD on autophagy. Changes in citrate synthase and mitochondrial
proteins combined with the ultrastructural alterations found in adipose tissue
suggest that HFD may promote mitochondrial remodeling and activate mitophagy
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Figure 10. Ultrastructure of white adipose tissues from lean and obese
mice. Representative transmission electron micrographs of epididymal adipose
tissues derived from mice fed a LFD or HFD for 6 weeks. (A) Ultrastructure of
mitochondria in adipose tissues from LF-fed mice: (i) micrograph of adipocytes in
areas close to the nucleus; (ii) higher magnification of panel i; (iii) a cytosolic
compartment containing a mitochondrion found protruding into the fat locule; and
(iv) an elongated mitochondrion in juxtaposition to the fat locule. (B)
Ultrastructure of adipose tissue derived from HF-fed mice: (i) An elongated
mitochondrion next to an autophagosome; (ii) an autophagosome in close
proximity to a vacuole containing electron-dense material; (iii) magnified image of
panel ii; (iv) protrusion of cytosolic compartment containing an atypical
mitochondrion; and (v) mitochondrion that appears to be undergoing fission.
Asterisks (*) indicate autophagosomes; small arrows indicate collagen;
mitochondria (M), nucleus (N), vacuole lipid droplet (LD).
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in WAT. To examine this possibility, we measured markers of mitophagy and
autophagy in adipose tissues from mice fed a LFD or HFD. The E3 ubiquitin
ligase Parkin, which has been shown to accumulate in mitochondria destined for
degradation

293

, was increased 2.3-fold by 6 weeks of HFD and nearly 2-fold by

12 weeks of HFD (Fig. 11A,B).

Furthermore, the kinase Pink1—critical for

identifying mitochondria destined for autophagy

293

—was also increased by

nearly 40% with HFD. Combined with the presence of autophagosomes and
mitochondrial alterations observed by EM (Fig. 10), this suggests that autophagy
may be involved in the metabolic remodeling of adipocytes in the expanding
adipose organ and protein indicators of autophagy were examined. As shown in
Fig. 11C–H, levels of p62 and LC3-I were diminished significantly and the LC3II/LC3-I ratio was increased more than 2-fold in mice fed a HFD for 6 weeks in
comparison with those placed on LFD. There was no significant difference in
total protein abundance of protein-ubiquitin and LC3-II.

Discussion
This study demonstrates coordinated changes in adipose tissue
metabolism that contribute to the “whitening” program during obesity. Using
metabolomics analysis, we identified that lipid and amino acid metabolism was
significantly significantly changed by HFD.

Importantly, these analyses were

independent of inflammatory cell infiltration and are therefore unlikely to be
confounded by changes in cell composition of the fat depot. The metabolomics
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Figure 11. Evidence for activation of mitophagy in WAT of obese mice.
Immunoblot analysis of markers of mitophagy and autophagy: (A) Western blots
of Parkin and Pink 1 in adipose tissues from mice fed a LFD or HFD for 6 weeks
(left panels) or 12 weeks (right panels); and (B) Quantification of Parkin and
Pink1 abundance from panel E. n = 4 per group; *p<0.05 vs. LFD. n = 4 per
group; *p<0.05 vs. 6 wk LFD, #p<0.05 vs 12 wk LFD. (C) Representative Western
blots of ubiquitinated proteins, p62, and LC3 in mice fed a LFD or HFD for 6
weeks. (D) Quantification of protein-ubiquitin abundance. (E) Quantification of
p62 abundance. (F) Quantification of LC3-I abundance. (G) Quantification of
LC3-II abundance. (H) Quantification of the LC3-II/LC3-I ratio. n = 10 per group;
*p<0.05 vs. LFD.
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dataset also indicated possible changes in energy metabolism. The Krebs cycle
intermediate, succinate, was significantly elevated in adipose tissue from obese
mice. Further experiments identified early decreases in citrate synthase activity
and explant oxygen consumption that coincided with decreased expression of
pgc1a; yet diminishment in citrate synthase activity was independent of
decreases in mitochondrial abundance, as indicated by mtDNA measurements
and the abundance of electron transport chain subunits. Evidence of
mitochondrial remodeling was found with 6 weeks of HFD, and elevation of the
mitophagy markers Parkin and Pink1 persisted through 12 weeks of feeding. The
decrease in p62 and LC3-I and elevation of the LC3-II/LC-I ratio in WAT from
obese mice support the notion that autophagic flux is increased in adipocytes of
mice fed a high-fat diet. Collectively, these studies suggest a progressive
remodeling of adipocyte metabolism under conditions of nutrient excess that
involves downregulation of mediators of mitochondrial biogenesis, mitochondrial
remodeling, and potential activation of the mitophagic program.
A major goal of this study was to understand changes in adipose tissue
biology and metabolism that occur with obesity. This is important because such
key metabolic features that change with obesity could become targets for antiobesity or insulin-sensitizing therapies. By 6 weeks of HFD, mice demonstrate
profoundly increased fat mass, decreased systemic VO 2, VCO2 and RER, and
insulin resistance. Although adipose tissue inflammation is apparent by the 10 th12th week of HFD in this model

294, 295

, 6 weeks of HFD was insufficient to

produce a robust inflammatory response in adipose tissue (e.g., see Fig. 5 and
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155, 295

).

In addition, no increase in plasma levels of sensitive markers of

inflammation such as IL-6 were identified at 6 weeks of HFD (IL-6 (pg/ml): LFD,
23.6±7.5; HFD, 18.8±4.2).

The absence of significant levels of inflammation

therefore allowed us to examine how obesogenic changes due to HFD regulate
adipose tissue metabolism without the confounding features of highly energetic
infiltrating cells such as macrophages 296.
Metabolomic analyses showed several metabolic pathways affected in
obesity.

These include glycerolipid metabolism, amino acid metabolism, and

energy and glucose metabolism. HFD decreased levels of long-chain fatty acids
in adipose tissue, and, coupled with significant decreases in glycerol and 1palmitoylglycerol,

is

consistent

with

an

increase

in

lipogenesis.

Glycerophosphoethanolamine (GPEA), one of the few metabolites that increased
in adipose tissue from obese mice, could be elevated as a result of
phosphatidylethanolamine (PE) breakdown. This is consistent with the decreased
abundance of 1-palmitoleoylglycerophosphoethanolamine and lysoPE species in
adipose tissue from HF-fed mice. Increased GPEA could also be due to
limitations in the rate of its hydrolysis: GPEA can be hydrolyzed by enzymes
such as glycerophosphodiester phosphodiesterase to form glycerol-3-phosphate
(G3P) 297, which is required for the formation of triglycerides and thus would likely
be in high demand in expanding adipocytes

298

.

Demand for G3P may also be met by glycolysis and glyceroneogenesis,
or, in some tissues, from the recycling of glycerol by glycerol kinase
69

298

. In our

study, G3P was significantly decreased, suggesting that it might be used quickly
to accommodate lipid storage. The glycolytic intermediate glucose-6-phosphate
was decreased as well, which suggests perturbations in adipocyte glucose
metabolism. Indeed, pdk4 expression, which regulates pyruvate dehydrogenase
activity, was decreased by HFD; it is then plausible that the decrease in pdk4
299

may promote the glyceroneogenic formation of G3P

via cataplerosis

300

. The

possibility that systemic glucose metabolism was affected by HFD is supported
by the lower abundance of 1,5-anhydroglucitol in samples from mice fed a HFD.
Plasma 1,5-anhydroglucitol (1,5-AG), is distributed to all organs and tissues and
is a validated marker of short-term glycemic control

301, 302

. Hence, even though

fasting glucose levels are not different after 6 weeks of HFD

286

, the decrease in

this metabolite is in agreement with insulin resistance in skeletal muscle and liver
occurring at 6 weeks of HFD 155.
The increase in stearoyl sphingomyelin in adipose tissue from mice fed a
HFD may be particularly significant. Sphingomyelin (SM; d18:1/18:0)—which in
humans is the only membrane phospholipid not derived from glycerol—is a type
of sphingolipid found in cell membranes that consists of oleic acid attached to the
C1 position and stearic acid attached to the C2 position. Deficiency of enzymes
involved in sphingomyelin synthesis have been shown to protect against dietinduced obesity and insulin resistance

303,

304

, and the breakdown of

sphingomyelin could yield significant amounts of ceramide, which inhibits insulin
signaling

305

.

Hence, the elevated levels of sphingomyelin could poise

adipocytes to release significant amounts of ceramide if acted upon by
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sphingomyelinases. Although ceramides were not measured in these analyses,
HFD has been shown to increase plasma and adipose ceramides in mice by
more than 300%

306

. Interestingly, depleting ceramides in mice fed a HFD

increases oxygen consumption and citrate synthase activity as well as preserves
PGC1 expression

307, 308

, all of which were decreased by HFD in the current

study. Ceramide also alters membrane permeability, inhibits electron transport
chain function and promotes oxidative stress

200

, which is consistent with the

evolving hypothesis that ceramide (and by proxy excess SM) induces
mitochondrial stress 305.
In addition to changes in lipid and glucose metabolism, metabolites in the
amino acid and energy metabolism pathways were also remarkably changed by
HFD. Recent studies suggest that changes in amino acid metabolism may be
critical to the development of obesity and insulin resistance.

In particular,

pathway impact analyses showed that BCAA and phenyalanine, tyrosine, and
tryptophan metabolism were significantly impacted by diet. In obese and insulinresistant humans, these amino acids are elevated systemically (reviewed in

309

),

and changes in several amino acid classes, including BCAAs and Phe, Tyr and
Trp, are associated with metabolic risk factors in humans

310

. Although there is a

clear relationship among amino acids, insulin resistance and obesity in animal
models, the mechanistic interpretations are less clear. For example, increasing
circulating BCAAs in mice by preventing BCAA catabolism prevents diet-induced
obesity and insulin resistance in mice
rats increases insulin resistance

311

, whereas feeding BCAAs to high fat-fed

312

. Levels of amino acids in adipose tissues
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appear to be important because BCAA metabolism in adipose tissues modulates
levels of circulating BCAAs

313

. In our study, we found that several amino acids

were decreased in abundance in adipose tissues from mice fed a HFD for 6
weeks. This could be due to changes in the catabolic flux of BCAAs, which
occurs in the mitochondrial matrix.
While most studies show a decrease in BCAA catabolism in obesity

309

,

our data are most consistent with an increase in BCAA catabolism. BCAA
catabolism results in the formation of acetyl CoA and succinyl CoA, the latter of
which can be converted to succinate by hydrolysis and release of CoA by
succinate thiokinase. Interestingly, succinate was one of the few metabolites that
were significantly increased in WAT from HF-fed mice.

Other Krebs cycle

intermediates, such as citrate and malate, were not changed in abundance. This
would appear to suggest an influx of carbon from BCAA catabolism into the
Krebs cycle, which might be sufficient to sustain concentrations of other citric
acid cycle intermediates or impart energetic changes.
Interestingly, adipose explants derived from mice fed a HFD showed an
apparent decrease in the rate of mitochondrial oxygen consumption; however,
when the OCR rates were normalized to the wet weight of each explant the OCR
was similar in adipose tissue from HF- and LF-fed mice. Given the fact that there
was a 3-fold increase in adipocytes due to lipid accumulation, it is likely that the
decreases in the apparent mitochondrial OCR are due simply to a decreased
number of adipocytes in the explants due to an increased volume of triglycerides,
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which comprises a large portion of the adipose tissue wet weight. Thus, despite
extensive remodeling, mitochondrial function remains preserved. However,
because the basal oxygen consumption in the explants was unaffected, it would
suggest increased non-mitochondrial oxygen consumption potentially due to an
increase in cytosolic oxidase activity
possibility is consistent with

314, 315

in WAT from high-fat fed mice. This

previous work showing an increase in adipose

tissue oxidative stress in obsese mice, due to an increase in the expression of
NADPH oxidase and downregulation of antioxidant enzymes

316-320

.

Despite no changes in mitochondrial number or oxygen consumption,
there was a remarkable decrease in citrate synthase activity by HFD. This was
accompanied by an increase in the gene expression of some subunits (e.g.,
cox7a1) in the adipose tissue of obese mice. These observations suggest that
HFD promotes an early remodeling of mitochondria to accommodate for shifting
metabolic needs and substrate availability. Reasons for increased cox7a1 gene
expression and the augmented response of adipose explants from 6 week high
fat-fed mice to FCCP are currently unclear. We speculate that the enhanced
response to FCCP relative to the basal OCR could be due to increased substrate
delivery to adipose tissue mitochondria in high fat-fed mice, which occurs only
when the proton motive force is diminished with the uncoupler. Cox7a1, is a
heart and muscle-specific subunit, which is also present in brown adipocytes.
This subunit has been shown to be increased in the WAT of fattening cattle

321

.

While reasons for the increase in this subunit are not clear, it is possible that its
increase may be an adaptive response to dissipate excess energy in the
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adipocyte. Further studies are required to assess fully the role of this subunit in
mediating energetic changes in WAT during obesity.
With prolonged high fat feeding (i.e., 12 weeks), decreases in
mitochondrial mass do appear to occur, which is supported both by our results
showing decreases in mitochondrial matrix and inner membrane proteins as well
as by published studies showing decreased mitochondrial mass in WAT of
severely obese mice

161, 283

and humans

322

. These data are consistent also with

published data showing a decrease in adipocyte mitochondrial function in obese
humans, independent of adipocyte size

322

.

Electron micrographs showed mitochondria appearing to undergo fission
in adipose tissue from HF-fed mice, and autophagosomes were found adjacent
to vacuolated structures containing electron-dense material and to mitochondria.
This suggested that both mitochondrial remodeling and autophagy may be
induced by HFD. That Parkin and Pink1 were also increased in adipose tissues
from obese mice would support the notion that mitophagy is induced by HFD.
Previous studies show that Pink1 accumulating within mitochondria recruits
Parkin, which ubiquitinates mitochondrial proteins that are then recognized by
autophagy adaptor proteins such as p62. The p62 then binds to LC3 which
sequesters mitochondria into autophagosomes for degradation

293

. Although

LC3-II and ubiquitinated proteins were not significantly changed with HFD, the
abundance of p62 was decreased, which is consistent with an increase in
autophagic flux

323

. Moreover, when autophagy is inhibited, the abundance of
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both LC3-I and p62 have been shown to increase

324, 325

, and, in our study, both

p62 and LC3-I were decreased and the LC3-II/LC3-I ratio was increased. These
data would then be consistent with the notion that autophagy is increased in
WAT of high fat-fed mice. However, a limitation of this study is that autophagic
flux was not measured. Nevertheless, the aggregate of ultrastructural and
immunological data, combined with published data showing that autophagy is
increased in adipocytes from obese humans and mice

326-328

, suggest that HFD

apparently increases autophagy and perhaps mitophagy in WAT.
The loss of mitochondria shown to occur by the 12 th week of HFD would
then appear to suggest a role for autophagic degradation of mitochondria in the
“whitening” of adipose tissue. Deletion of essential autophagy genes such as
atg7 in mice results in resistance to obesity and promotion of a brown-like
adipose tissue phenotype having more mitochondria and higher rates of
substrate oxidation

325

. Furthermore, mouse embryonic fibroblasts (MEFs)

isolated from atg5−/− mice accumulate less lipid when stimulated to develop into
adipocytes

325

, suggesting that autophagy is essential for lipogenesis and WAT

expansion. Interestingly, systemic knock-out of Parkin prevents diet-induced
obesity and insulin resistance; however, this was shown to be due to decreased
uptake of fat from the diet

329

, indicating that functions of Parkin are not exclusive

to mitophagy. Nevertheless, the Pink1-Parkin pathway has been shown to
promote both mitophagy and selective respiratory chain turnover in vivo

330

,

which is consistent with our findings in adipose tissues of obese mice. The use of
genetic models with adipose tissue-selective overexpression or deletion of Parkin
75

would further help to understand how mitophagy regulates adipose tissue
phenotype.
In summary, in this study we identified key metabolic changes that occur
during WAT expansion. These coordinated changes occur before the infiltration
of inflammatory cells and include: loss of mitochondrial biogenetic capacity;
dysregulation

of

glycerolipid,

sphingolipid

and

amino

acid

metabolism;

mitochondrial remodeling; and changes suggestive of activation of mitophagy.
Based on these observations, we posit that such metabolic remodeling
contributes to the whitening of adipose tissue during obesity.
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CHAPTER III
OVEREXPRESSION OF ENDOTHELIAL NITRIC OXIDE S.NTHASE
PREVENTS DIET.INDUCED OBESIT. AND REGULATES
ADIPOC.TE PHENOT.PE

Introduction
Obesity and type 2 diabetes (T2D) have become major health challenges
worldwide. Current data show that approximately 1.5 billion adults aged 20 years
or older are overweight, and 10% are obese 1. In the US, one-third of the
population meets the criteria for metabolic syndrome

3, 4

. While lifestyle changes

and lack of exercise are important risk factors for weight gain

279, 331

, excessive

caloric intake appears to be one key factor fueling the epidemic of obesity. Poor
dietary habits negatively affect a broad range of cardiovascular functions and
promote the onset of T2D 4.
Although it is currently believed that obesity results from excessive
nutrient consumption

11, 332

, i.e., more calories are ingested than are utilized,

recent evidence suggests that the balance between nutrient intake and energy
expenditure is complex and is regulated by many inter-dependent mechanisms
332

. Several studies indicate that obesity and insulin resistance may be distinct

sequelae of nutrient excess

333

. Hence, to stem the tide of the epidemics of
77

T2D and obesity, it is important to understand the relationship between obesity
and insulin resistance as well as the physiological processes that regulate their
development.
Accumulating evidence suggests that the vascular endothelium regulates
insulin action. In humans, states of obesity and insulin resistance are
characterized by endothelial dysfunction, impaired vasodilation and insulin
resistance

334

; and in rats, inhibition of endothelial nitric oxide synthase (eNOS)

decreases insulin-stimulated uptake of glucose by skeletal muscle, suggesting
that eNOS may be a key regulator of metabolic homeostasis. This role of eNOS
is further corroborated by observations that deletion of the eNOS gene in mice
induces insulin resistance

335,

336

and impairs fatty acid oxidation

337

.

Nevertheless, the role of eNOS in regulating metabolic changes that contribute to
obesity under conditions of nutrient excess is not well understood. In particular, it
is unclear whether eNOS could prevent or attenuate diet-induced adiposity and
insulin resistance.
To understand the metabolic role of eNOS, we studied effects of high fat
diet in mice overexpressing eNOS. Our hypothesis was that increasing eNOS
levels mitigates effects of high fat feeding by regulating adipose tissue
metabolism. We found that eNOS-transgenic (eNOS-TG) mice were resistant to
diet-induced weight gain, but not glucose intolerance. These findings reveal a
new anti-obesogenic role of eNOS and its favorable influence on adipose tissue
metabolism.
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Experimental Procedures
Animal studies: The B6.BKS(D)-Leprdb/J (db/db) mice and C57BL/6J (wild-type;
WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The
eNOS-TG mice, which express bovine eNOS under the control of the
preproendothelin-1 promoter

338

, were maintained on the C57BL/6J background.

At 8 weeks of age, male mice were placed on either a 10% low fat diet (LFD;
Research Diets, Inc., #D12450B) or a 60% high fat diet (HFD; Research Diets
Inc., #D12492) and maintained for 6–15 additional weeks. Water and diet were
provided ad libitum. Body weights were recorded weekly. During the 7 th and 13th
weeks of feeding, glucose and insulin tolerance tests were performed. Pyruvate
tolerance tests were performed only after the 13th week of feeding; all other
variables were evaluated after euthanasia. All procedures were approved by the
University of Louisville Institutional Animal Care and Use Committee.

Expression analyses: Tissue homogenates were prepared and used for
Western blot protein expression analysis. For quantitative RT-PCR, RNA
extracted from tissues was used to assess pgc1a, cytb6, gapdh, ppara, and
pparg expression using commercially available primers (SABiosciences,
Valencia, CA).

Glucose, insulin, and pyruvate tolerance tests: As described before

339

,

glucose tolerance tests were performed following a 6 h fast by injection (i.p.) of
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D-glucose (1 mg/g) in sterile saline. Insulin tolerance tests were performed on
nonfasted animals by i.p. injection of 1.5 U/kg Humulin R (Eli Lilly, Indianapolis,
IN). After a 6 h fast, pyruvate tolerance tests were performed as described

340

.

Biochemical analyses: Plasma lipids, proteins, and metabolites were measured
using a Cobas Mira Plus 5600 Autoanalyzer (Roche, Indianapolis, IN) or Luminex
kits (Millipore, Billerica, MA, USA). Plasma levels of non-esterified free fatty
acids and glycerol were measured by ELISA (Wako Chemicals, Richmond, VA
and Cayman Chemical, Ann Arbor, MI, respectively). Nitrite and nitrate levels
were measured as described 341.

Adipocyte size measurements: Adipose tissue excised at the time of
euthanasia was either snap-frozen at –80°C or fixed in 10% formalin (Leica),
paraffin-embedded, and sectioned. Sections were stained in hematoxylin and
eosin. Adipocyte cross-sectional area was measured using Nikon Elements
software. To assess relative mitochondrial abundance, sections were stained
with MitoID Red (Enzo Life Sciences, Farmingdale, NY). Crown-like structures
and inflammatory cells indicative of adipose tissue inflammation were measured
as described before 287, 294.
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Body composition and calorimetry: Body composition was measured by dualenergy X-ray absorptiometry using a mouse densitometer (PIXImus2; Lunar,
Madison, WI). Whole body energy expenditure, respiratory exchange ratio, food
consumption, and locomotion, ambulatory and fine movements were measured
using a physiological/metabolic cage system (TSE PhenoMaster System, Bad
Homberg, Germany).

Immunostaining of adipose tissue: Capillary density was quantified in paraffinembedded sections using fluorescently labeled isolectin B4 as described

342

.

Nitrotyrosine adducts were measured in paraffin-embedded tissues using antinitrotyrosine and goat-anti-rabbit IgG-Cy3 antibodies.

Adipose tissue bioenergetic measurements: The oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) of intact adipose tissue
explants were measured using a Seahorse XF24 analyzer (Seahorse Bioscience,
Billerica, MA). Briefly, freshly isolated epididymal adipose tissue was rinsed with
unbuffered DMEM (Dulbecco’s modified Eagle’s medium, pH 7.4). The adipose
tissue was cut into sections, and 10 mg were placed in each well of an XF 24
Islet Capture Microplate (Seahorse Bioscience, Billerica, MA). The tissue was
then covered with a screen, which allows free perfusion while minimizing tissue
movement. Unbuffered DMEM (500 μl) supplemented with 50 μM BSAconjugated palmitic acid, 200 μM L-carnitine, and 2.5 mM D-glucose was then
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added to each well. At least two replicates from each animal were used for the
assay, and each tissue section was examined to ensure absence of large
vessels (which can skew oxygen consumption measurements). The plate was
incubated at 37°C in a non-CO2 incubator for 1 h prior to extracellular flux
analysis. After three baseline measurements, a mixture of antimycin A (10 μM)
and rotenone (1 μM) was injected. Following injection, the OCR was closely
monitored until the rates stabilized, and then the experiment was terminated.

Metabolomic analysis of adipose tissue: White adipose tissue from the
epididymal fat pad of fasted mice (16 h fast) was collected and snap-frozen in
liquid nitrogen. At the time of analysis, sample metabolites were extracted with
methanol. A recovery standard was introduced at the beginning of the extraction
process. The extracted samples were split into equal parts for analysis on the
GC/MS and LC/MS/MS platforms. Also included were several technical replicate
samples created from a homogeneous pool containing a small amount of all
study samples. Samples were placed briefly on a TurboVap ® (Zymark) to remove
the organic solvent. Each sample was then frozen and dried under vacuum.
Samples were then prepared for the appropriate instrument, either LC/MS or
GC/MS

LC/MS, LC/MS2: The LC/MS portion of the platform was based on a Waters
ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which
82

consisted of an electrospray ionization (ESI) source and linear ion-trap (LIT)
mass analyzer. The sample extract was split into two aliquots, dried, then
reconstituted in acidic or basic LC-compatible solvents, each of which contained
11 or more injection standards at fixed concentrations. One aliquot was analyzed
using acidic positive ion optimized conditions and the other using basic negative
ion optimized conditions in two independent injections using separate dedicated
columns. Extracts reconstituted in acidic conditions were gradient eluted using
water and methanol both containing 0.1% formic acid, while the basic extracts,
which also used water/methanol, contained 6.5 mM ammonium bicarbonate.
The MS analysis alternated between MS and data-dependent MS2 scans using
dynamic exclusion.

GC/MS: Samples destined for GC/MS analysis were re-dried under vacuum
desiccation for a minimum of 24 hours prior to being derivatized under dried
nitrogen using bistrimethyl-silyl-triflouroacetamide. The GC column was 5%
phenyl and the temperature ramp was from 40° to 300° C in a 16 minute period.
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning singlequadrupole mass spectrometer using electron impact ionization. The instrument
was tuned and calibrated for mass resolution and mass accuracy on a daily
basis. The information output from the raw data files was automatically extracted
as discussed below.

83

Accurate mass determination and MS/MS fragmentation: In addition to the
LIT front end, the LC/MS portion of the platform had a Fourier transform ion
cyclotron resonance (FT-ICR) mass spectrometer backend. For ions with counts
greater

than

2

million,

an

accurate

mass

measurement

could

be

performed. Accurate mass measurements could be made on the parent ion as
well as fragments. The typical mass error was less than 5 ppm. Fragmentation
spectra (MS/MS) were typically generated in data-dependent manner, but if
necessary, targeted MS/MS could be employed, such as in the case of lower
level signals.

QA/QC: Instrument variability was determined by calculating the median relative
standard deviation (RSD) for the internal standards that were added to each
sample prior to injection into the mass spectrometers. Overall process variability
was determined by calculating the median RSD for all endogenous metabolites
(i.e., non-instrument standards) present in 100% of the samples, which are
technical replicates of pooled samples. Values for instrument and total process
variability were 5% for internal standards and 15% for endogenous biochemicals,
respectively. For QA/QC purposes, a number of additional samples are included
with each day’s analysis. Furthermore, a selection of QC compounds was added
to every sample, including those under test. These compounds were carefully
chosen to avoid interference with the measurement of the endogenous
compounds.
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Metabolite identification: Compounds were identified by comparison to library
entries of purified standards or recurrent unknown entities.

Identification of

known chemical entities was based on comparison to metabolomic library entries
of purified standards. More than 1000 commercially available purified standard
compounds had been acquired registered into the Metabolon Laboratory
Information Management System (LIMS) for distribution to both the LC and GC
platforms for determination of their analytical characteristics. The combination of
chromatographic properties and mass spectra gave an indication of a match to
the specific compound or an isobaric entity.

Curation: A variety of curation procedures were carried out to ensure that a high
quality data set was made available for statistical analysis and data
interpretation. The QC and curation processes were designed to ensure accurate
and consistent identification of true chemical entities, and to remove those
representing

system

artifacts,

mis-assignments,

and

background

noise.

Visualization and interpretation software were used to confirm the consistency of
peak identification among the various samples. Library matches for each
compound were checked for each sample and corrected if necessary.

Bioinformatics: The bioinformatics system consisted of four major components,
the LIMS system, data extraction and peak-identification software, data
processing tools for QC and compound identification, and a collection of
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information interpretation and visualization tools. The purpose of the LIMS
system was to enable fully auditable laboratory automation through a secure,
easy to use, and highly specialized system. The scope of the LIMS system
encompasses sample accessioning, sample preparation and instrumental
analysis and reporting and advanced data analysis. Some of the subsequent
software systems were grounded in the LIMS data structures, which have been
modified to leverage and interface with the Metabolon information extraction and
data visualization systems, as well as other data analysis software such as
Metaboanalyst (http://www.metaboanalyst.ca/).

Metabolomic analysis: The general outline for how metabolomic data were
analyzed is shown in Fig. 22. Metabolites with missing values were imputed by
replacing missing values with half of the minimum positive value in the original
data. Metabolites with greater than 57% of values missing were omitted from the
analysis. Data were then quantile normalized within replicates after log
transformation. This step was performed to transform the intensity values so that
the distribution was more Gaussian. T-test statistical comparisons were then
performed. Further univariate and multivariate analysis, such as correlation
analysis, principal component analysis and partial least squares discriminant
analysis

was

then

performed

using

(http://www.metaboanalyst.ca/) 288, 343.
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the

Metaboanalyst

2.0

software

Statistical analyses: Data are expressed as mean ± SEM. Multiple groups were
compared using one-way or two-way ANOVA, followed by Bonferroni post-tests.
Unpaired Student’s t test was used for direct comparisons. Statistical analyses
were performed with the program “R” http://cran.r-project.org/, Metaboanalyst
(http://www.metaboanalyst.ca/), and/or GraphPad 5.0. A P value less than 0.05
was considered significant.

Results
Nutrient excess alters eNOS abundance.

To study effects of obesity and

diabetes on eNOS protein levels, C57BL/6J mice were placed on a high fat diet
155

, and db/db mice were used as a model of T2D

344

. High fat feeding for 6 and

12 weeks resulted in a profound decrease in eNOS levels in adipose tissue (Fig.
12A,B), with no statistically significant changes in the aorta (Fig. 12A,C) or
skeletal muscle (Fig. 13A,B). Similar changes were observed in 20 week old
db/db mice, in which eNOS in the adipose tissue was undetectable despite a lack
of change in eNOS levels in most other tissues. Interestingly, eNOS expression
was increased in hearts of db/db mice (Fig. 13A,C), which might be a
compensatory change in response to an increase in NO demand. These data
show that both obesity and diabetes result in tissue-specific changes in eNOS
expression with a profound and selective decrease in eNOS levels in the adipose
tissue. This decrease in eNOS in adipose tissue is consistent with previous
reports in obese humans

158, 159

and in mouse models of obesity
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161

, indicating

that the expansion of adipose tissue establishes a state of chronic eNOS
deficiency.

Overexpression of eNOS prevents diet-induced obesity. To examine the role
of eNOS, we used eNOS-TG mice

338

. Previous studies have shown that these

mice reproduce in a Mendelian fashion, maintain normal growth characteristics,
and are protected from numerous pathologies including myocardial
346

, lung

347

, and vascular injury

348

as well as sepsis

345

, hepatic

349

. In comparison with WT

mice, hemizygous mice showed a 4-fold increase in eNOS levels in the aorta,
with no significant change in eNOS levels in the adipose tissue (Fig. 12D,E). In
contrast, in homozygous mice there was a 2-fold increase in eNOS in the
adipose tissue and a 6-fold increase in the aorta. The eNOS in TG animals
localized exclusively with isolectin staining (Fig. 14), indicating that the transgene
was expressed only in the vasculature

338, 350

.

Plasma from eNOS-TG mice

showed increased L-citrulline and nitrite levels when compared with WT mice
(Fig. 15A,C), and adipose tissue from eNOS-TG mice demonstrated an increase
in L-citrulline (Fig. 15B). Due to high variability, there were no significant
differences in nitrate or nitrite in adipose tissue (Fig. 15D) perhaps due to other
confounding factors, such as nitrite/nitrate found in the diet or reduction of nitrite
to NO.
When placed on a high fat diet for 6 weeks, the homozygous eNOS-TG
mice gained 50% less weight than WT mice, and this effect persisted for 12
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weeks (Fig. 16B,C). Food intake was not different between WT and eNOS-TG
mice (Fig. 16D). A more modest resistance to weight gain was also observed in
hemizygous eNOS-TG mice (Fig. 13-D), perhaps due to lower adipose tissue
eNOS levels in these mice compared with homozygous eNOS-TG mice. Hence,
for all subsequent studies, only eNOS homozygous mice were used.
The transgenic mice maintained a higher percent of lean mass (Fig. 16G),
although the tibia length in transgenic mice was only slightly smaller than in WT
mice (Fig. 16H). These observations indicate that overexpression of eNOS
decreases adiposity and prevents weight gain induced by high fat diet.

eNOS overexpression increases whole body metabolism. To determine how
eNOS overexpression affected whole-body metabolism, we measured oxygen
consumption (VO2), carbon dioxide production (VCO2), and activity in high fat-fed
WT and eNOS-TG mice over the course of a 12 h dark period and a 4.5 h light
period. The fact that food intake was not different between WT and TG mice (Fig.
16D), indicates that the lean phenotype of eNOS-TG mice is not due to a
decrease in food consumption. This view is reinforced by the observation that
high fat feeding increased plasma cholesterol and leptin to similar levels in WT
and eNOS-TG mice (Table 2). In comparison with WT mice, eNOS-TG mice
showed higher mean VO2 and VCO2 rates throughout the dark and light periods
(Fig. 16I,J), with no change in the respiratory exchange ratio (RER; Fig. 16K).
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Figure 12. Nutrient excess alters tissue eNOS levels. Tissue levels of eNOS
from mice fed a low fat (LFD) or high fat diet (HFD) for 6 or 12 weeks; agematched db/db mice were included as an additional model of T2D: (A)
Representative Western blots of eNOS from epididymal adipose tissue and
aorta. (B,C) Quantification of eNOS expression from panel A. n = 3–4 per
group;**p<0.01 vs. 6 week LFD. (D,E) Levels of eNOS in adipose tissue and
aorta from wild-type (WT), littermate eNOS-TG hemizygous, and eNOS-TG
homozygous mice. n = 3 per group; **p<0.01 vs. indicated groups
.
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Figure 13. Effects of nutrient excess on eNOS levels, and body weight gain
of mice expressing different levels of eNOS. Panels A–C: Immunoblot
analysis of eNOS expression in skeletal muscle and heart in C57BL/6J mice fed
a low fat diet (LFD) or high fat diet (HFD) for 6 or 12 weeks; db/db mice agematched to the 12 week feeding group were included as an additional model of
metabolic syndrome. (A) Representative Western blots of eNOS expression in
skeletal muscle and heart; (B) Quantification of skeletal muscle eNOS
expression; and (C) Quantification of heart eNOS expression. n = 3–4 per
group;***p<0.001 vs. WT LFD. Panel D: Weight gain of wild-type, littermate
eNOS hemizygous, and eNOS homozygous mice fed HFD over the course of 12
weeks. n = 4–8 per group.
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Figure 14. The eNOS transgene localizes to the vasculature in adipose
tissue. Immunofluorescence images of epididymal adipose tissue from eNOSTG mice: Adipose tissues were fixed, sectioned, and stained with DAPI (blue),
isolectin (green), and eNOS antibody (red).
localization of the eNOS and isolectin signals.
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The overlay shows the co-
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Figure 15.

Measurements of eNOS and NO metabolites in plasma and

adipose tissue. Mice were fed a LFD or HFD for 6 weeks and citrulline, nitrite,
and nitrate levels in the plasma and adipose tissue were analyzed by LC/MS or
HPLC. Panels A and B: Relative levels of L-citrulline from (A) plasma and (B)
adipose tissue; Panels C and D: Measurements of nitrite from (C) plasma and
(D) adipose tissue; Panels E and F: Measurements of nitrate from (E) plasma
#

and (F) adipose tissue. n = 6–7 per group; *p<0.05 vs. WT LFD; p<0.05 vs. TG
$

LFD; p<0.05 vs. WT HFD.

96

97

Activity levels, assessed by horizontal activity count (beam breaks)
showed similar patterns and levels of activity, and total ambulatory activity was
not significantly different (Fig. 16L). Taken together, these observations suggest
that on a high fat diet, eNOS-TG mice maintain a higher metabolic rate than WT
mice. This increase in systemic metabolism, however, cannot be attributed to
thyroid hormones, because plasma levels of triiodothyronine (T3) and thyroxine
(T4) in WT and eNOS-TG mice were not significantly different (Fig. 17).
Measurements of body composition by dual-energy X-ray absorptiometry
(Dexascan) showed that after 6 weeks of high fat feeding, the body fat content
was much lower in eNOS-TG mice than in non-transgenic mice (Fig. 16E,F).

Effect of eNOS on diet-induced insulin resistance. Because we found that
eNOS overexpression prevented diet-induced weight gain, we expected
concurrent changes in insulin resistance. Indeed, we found that overexpression
of eNOS completely prevented diet-induced hyperinsulinemia (Table 2), although
plasma levels of adiponectin and resistin were not affected. This was associated
with a remarkably lower HOMA-IR score (WT low fat, 1.45±0.65; WT high fat,
34.4±5.3, p<0.05 vs. WT low fat; TG low fat, 6.9±3.1; TG high fat, 8.2±2.9,
p<0.05 vs. WT high fat). Moreover, even though 6 weeks of high fat feeding did
not significantly increase triglycerides or plasma non-esterified free fatty acids
(NEFA), both of these were decreased by 50% in the TG mice compared with
WT mice (Table 2).

We found no significant differences in plasma glycerol
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between groups (Table 2), suggesting that adipose tissue lipolysis was not
affected. Collectively, these data indicate that overexpression of eNOS prevents
high fat diet-induced hyperinsulinemia and decreases plasma triglycerides and
fatty acids.
To examine how eNOS overexpression affects systemic glucose disposal,
WT and eNOS-TG mice were placed on a high fat diet for 6 weeks, and GTT and
ITT were performed. There was no significant difference in the basal blood
glucose levels in non-fasted WT and eNOS-TG mice (Fig. 18A). After a fast of 6
h, the plasma glucose levels of both high fat-fed groups were significantly
increased compared with the WT low fat-fed group. Fasting for 16 h resulted in
near normalization of blood glucose in WT mice; however, glucose levels in the
eNOS-TG mice remained slightly, but significantly, elevated (Fig. 18A). There
were no significant differences in plasma HbA1c in any group (Fig. 18B).
To test whether effects of the transgene would manifest after prolonged
feeding, we placed WT and eNOS-TG mice on high fat diet for 12 weeks and
assessed insulin resistance. At completion of the feeding protocol, the GTT and
ITT curves were superimposable suggesting that eNOS overexpression does not
affect diet-induced insulin resistance even after prolonged nutrient excess (Fig.
19A-D). Although, plasma glucose levels in non-fasted and 6 h-fasted mice were
not statistically different, a 16 h fast led to a greater decrease in blood glucose in
WT compared with TG mice (Fig. 19E), indicating that the TG mice were more
resistant to fasting-induced hypoglycemia, which could be due to increased
gluconeogenesis in the liver.
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Figure 16. eNOS prevents diet-induced obesity. Weight gain, adiposity, and
indirect calorimetry measurements from WT and eNOS-TG mice fed a low fat
(LFD) or high fat diet (HFD): (A) Body weights during 6 weeks of LF feeding, n =
22–26 per group; (B) body weights during 6 weeks of HF feeding, n = 26 per
group; (C) summarized weight gain over the course of 6 weeks and 12 weeks of
HF feeding, n = 28–29 per group for 6 week group, n = 4–7 per group for 12
week group; (D) food intake, n = 4 per group; (E) representative DexaScan
images of mice fed a LFD or HFD for 6 weeks; (F) body fat percentage, n = 8–12
per group; (G) lean mass percentage, n = 8–12 per group; and (H) tibia length for
mice fed a LFD or HFD for 6 weeks, n = 8–12 per group; (I) average oxygen
consumption (VO2); (J) average carbon dioxide production (VCO2); (K)
respiratory exchange ratio (RER); and (L) ambulatory counts. n = 4 per group;
*p<0.05, **p<0.01, and ***p<0.001 vs. indicated groups; #p<0.05 vs. WT HFD.
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Figure 17. Diet and genotype do not affect circulating free T3 or T4 levels.
Free triiodothyronine (T3) and thyroxine (T4) were measured in plasma from WT
and eNOS-TG mice that were fed LF or HF diets for 6 weeks. n = 4–6 per group.

102

103

104

To test this, we performed pyruvate tolerance tests, which did not show
remarkable differences between WT and TG mice (Fig. 19F,G), indicating that
resistance to hypoglycemia in TG mice may not be due to increased hepatic
production

of

glucose.

Collectively,

these

data

suggest

that

eNOS

overexpression does not significantly affect diet-induced insulin resistance or
glucose intolerance, but maintains glucose homeostasis during starvation.

Effect of eNOS on adipose tissue. Given our observations that obesity and
diabetes were associated with a selective decrease of eNOS levels in adipose
tissue and that eNOS-TG mice were resistant to diet-induced weight gain, we
measured changes in adipocyte area and size in epididymal fat pads. These
measurements revealed that high fat diet induced adipocyte hypertrophy leading
to a 3–4-fold increase in mean adipocyte area (Fig. 20A,B). Moreover, the high
fat diet promoted size heterogeneity in WT, but not eNOS-TG mice (Fig. 20C),
indicating

that

eNOS

overexpression

prevents

diet-induced

adipocyte

hypertrophy and size dispersion.
In murine models of diet-induced obesity, adipocyte hypertrophy is
associated with inflammation and accumulation of macrophages in adipose
tissue

351

. This is commonly recognized by the presence of crown-like structures

that appear between adipocytes

190, 287, 351

. In humans, obesity is similarly

associated with adipose tissue inflammation, and weight loss interventions such
as bariatric surgery improve endothelial function 352, 353.
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Figure 18. Effect of eNOS overexpression on indices of insulin resistance.
After 6 weeks of a low fat (LFD) or high fat diet (HFD), glucose tolerance and
insulin sensitivity were examined in WT and eNOS-TG mice: (A) Non-fasting and
fasting glucose levels; white bars, WT LFD; blue bars, eNOS-TG LFD; white
hatched bars, WT HFD; blue hatched bars, eNOS-TG HFD; (B) HbA1c; (C–E)
glucose tolerance tests; and (F–H) insulin tolerance tests. n = 14 per group;
*p<0.05 vs WT LFD or otherwise indicated groups.
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Figure 19. Measures of insulin resistance and gluconeogenesis in WT and
eNOS-TG mice fed a high fat diet for 12 weeks. After 12 weeks of HFD,
glucose tolerance and insulin sensitivity were examined in WT and eNOS-TG
mice: (A) Glucose tolerance test (GTT); (B) Insulin tolerance test (ITT); (C) GTT
area under the curve (AUC); (D) ITT AUC; (E) Blood glucose under non-fasted,
6-h-fasted and 16-h-fasted conditions; (F) Pyruvate tolerance test (PTT) was
used to determine differences in gluconeogenesis between the mice; and (G)
PTT AUC. n = 4 per group;*p<0.05 vs. WT.
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Therefore, we examined adipose tissue inflammation in WT and eNOS-TG mice
after 6 weeks of high fat diet. Analysis of adipose tissue showed no significant
difference in the abundance of crown-like structures between WT and TG mice
(Fig. 20A), and analysis of the adipose tissue stromal vascular fractions showed
no difference in total F480+ cells or changes in macrophage subtypes (Fig. 21).
These results are in accordance with studies showing that macrophage
accumulation and insulin resistance occur only with prolonged high fat feeding
(>10 weeks)155, 295 and suggest that the anti-hypertrophic effects of eNOS are not
associated with significant changes in adipose tissue inflammation, but are likely
to be related to favorable changes in metabolism that prevent lipid accumulation
and adipocyte expansion.

Metabolic changes in adipose tissues of eNOS-overexpressing mice. The
lean phenotype of eNOS-TG mice and their resistance to diet-induced weight
gain and adipocyte expansion clearly indicated that eNOS overexpression has a
significant impact on adipocyte metabolism. Therefore, to assess this impact, we
measured metabolite levels in epididymal adipose tissue of high fat-fed WT and
eNOS-TG mice using UHPLC/MS/MS and GC/MS. Spectral data were identified,
searched against a standard library, and quantified (Fig. 22). Internal standards,
including injection standards, process standards, and alignment standards were
used for quality control and to control for experimental and instrument variability.
This analysis led to the identification of 192 metabolites of which 37 were
significantly different between WT and eNOS-TG mice (Fig. 23A and Table 3).
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Figure 20. eNOS overexpression decreases diet-induced adipocyte
hypertrophy. Adipocyte size measurements from WT and eNOS-TG mice fed a
LFD or HFD for 6 weeks: (A) Representative hematoxylin and eosin-stained
images of adipose tissue from the epididymal fat pad (×20 magnification; scale
bar = 100 μm); (B) Mean adipocyte area; (C) Distribution of adipocyte sizes from
mice fed a LFD (upper panel) and a HFD (lower panel). n = 5 per group, *p<0.05
vs. WT LFD; #p<0.05 vs. WT HFD.
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Figure 21. Effects of high fat diet on macrophage subtypes in WT and
eNOS-TG mice. Macrophage subpopulations measured in epididymal adipose
tissues after 6 weeks of LFD or HFD: (A–D) Representative flow cytometry dot
+

plots of F4/80 adipose tissue macrophages from WT and eNOS-TG mice. (E)
Quantification of M1 macrophage subpopulations; (F) Quantification of M2
macrophage subpopulations; and (G) Quantification of macrophages doubly
positive for M1 and M2 macrophage markers. n = 6 per group.
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Figure 22. Flow chart illustrating procedure for metabolomic profiling of
adipose tissues. Mice were fed a HFD for 6 weeks. The adipose tissue was
then procured, and metabolites were extracted. The samples were divided for
GC/MS or LC/MS analysis. Following spectral analysis, the data were imputed,
normalized, and analyzed using Metaboanalyst 2.0 software.
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Although intermediates in the glycolytic pathway and TCA cycle were not
affected, there were significant increases in propionylcarnitine, acetylcarnitine, 3dehydrocarnitine, and isobutyrylcarnitine, some of which have been shown to
stimulate fatty acid oxidation

354, 355

. Higher levels of amino acids such as

threonine, methionine, valine, isoleucine, and leucine were also observed in TG
mice (Table 3). Multivariate and cluster analyses showed that these changes
were determining factors in the separation of the groups (Fig. 23B,C), and
pathway impact analysis (Fig. 23D) suggested that changes in amino acid
synthesis and degradation may be important features regulating the lean
phenotype of eNOS-TG mice. Plotting of the z-scores of metabolites from
adipose tissues of eNOS-TG and WT mice showed increases in short-chain
acylcarnitines as well as amino acids and their degradation products (Fig. 24A).
Metabolites correlating with citrulline levels showed a similar pattern of
metabolites (Fig. 24B). The adipose tissue metabolites in eNOS-TG mice shown
to be significantly different from WT mice equated to differences in urea
cycle/arginine metabolism, branched chain amino acid (BCAA) metabolism,
carnitine metabolism, purine metabolism, oxidative phosphorylation, and fatty
acid metabolism subpathways (Fig. 24C). Taken together, changes in metabolite
levels in the adipose tissue indicated that overexpression of eNOS stimulates
amino acid and fatty acid metabolism in adipose tissue.
Adipose tissue mitochondria are increased in eNOS-TG mice. Favorable
changes in BCAA and fatty acid metabolism are indicative of increased
mitochondrial activity. Previous studies have shown that BCAA increases
118

mitochondrial biogenesis and that this is attenuated in eNOS-null mice

356

. In

addition, it has been reported that NO triggers mitochondrial biogenesis in
adipocytes and that deletion of eNOS decreases mitochondrial content in
adipose tissue

357

. Based on this evidence, we hypothesized that the change in

BCAA and fatty acid metabolism in the adipose tissue of eNOS-TG mice may be
related to greater mitochondrial content. Indeed, adipose tissue, but not skeletal
muscle, from eNOS-TG mice showed significant increases in key mitochondrial
proteins such as COX4I1 and ALDH2 (Fig. 25A,C).

The increase in

mitochondrial proteins in TG adipose tissue could be due to remodeling of the
mitochondria or an increase in mitochondrial abundance. To distinguish between
these possibilities, sections of adipose tissue were stained with a non-membrane
potential-dependent mitochondrial stain, mitoID-Red.

As shown in Fig. 25E,

adipose tissue isolated from high-fat-fed eNOS-TG mice stained more strongly
than WT mice, indicating that the adipose tissue mitochondrial content was
higher in TG than WT mice. Indeed, adipocytes isolated from high fat-fed eNOSTG mice were more brown in color than those isolated from WT mice (Fig. 25F),
suggesting an increase in mitochondrial cytochromes. Indeed, in addition to
increased abundance of COX4I1 (Fig. 25A,C), the expression of the
mitochondrial gene cytochrome b6 (cytb6), was elevated 2-fold in eNOS-TG mice
(cytb6:gapdh ratios, fold change: WT, 1.0±0.1; eNOS-TG, 2.0±0.3; n=4–7/group,
p<0.05). That this increase in mitochondrial content may be due to increased
biogenesis is supported by our observation that in comparison with WT mice, TG
mice had higher adipose levels of PGC1α and Sirt3, as well as an increase in
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Figure 23. Metabolomic analyses of adipose tissues from high fat-fed mice.
Metabolomic analyses of epididymal adipose tissue metabolites from WT and
eNOS-TG mice fed HFD for 6 weeks: (A) Univariate analysis: t-tests of
compounds from adipose tissues. All metabolites above the dotted line were
found to be significantly different between WT and eNOS-TG mice (p<0.05).
Each of these metabolites is listed in Table 4; (B) Multivariate analysis: partial
least squares-discriminant analysis (PLS-DA); (C) Hierarchial clustering:
Heatmap and dendogram using the the most significantly different metabolites.
(D) The significant metabolites were subjected to pathway impact analysis using
Metaboanalyst MetPA and the Mus musculus pathway library. Fisher’s exact test
was used for overrepresentation analysis, and relative betweenness centrality
was used for pathway topology analysis. n = 14 animals: 7 WT HFD, 7 eNOS-TG
HFD.
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Figure 24. Overexpression of eNOS regulates intermediary metabolism in
adipose tissue. Metabolite analysis from adipose tissues of WT and eNOS-TG
mice fed HFD for 6 weeks: (A) z-score plots of significantly changed metabolites;
(B) Correlation analysis was assessed using the Spearman rank correlation test,
and metabolites that correlated with citrulline were then examined. (C) Superand sub-pathway distribution of adipose tissue metabolites found to be
significantly different between WT and eNOS-TG mice. n=14 animals: 7 WT HFD
and 7 eNOS-TG HFD.
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ppar and  (Fig. 25G); factors that are important activators of mitochondrial
biogenesis 284, 358-362.

Effect of eNOS on adipose tissue metabolic flux. To assess the functional
implications of our observations, we measured oxygen consumption in adipose
tissue explants using extracellular flux technology. As shown in Fig. 26B, adipose
tissue from eNOS-TG mice showed a significantly higher oxygen consumption
rate (OCR) compared with adipose tissue from WT mice. To determine the
contribution of mitochondria to the OCR, we treated explants with the electron
transport chain inhibitors antimycin A and rotenone. The stabilized rate measured
thereafter was used to calculate the mitochondria-derived OCR, which was 2-fold
higher in eNOS-TG compared with WT adipose tissue (Fig. 26C). No statistically
significant difference was observed in the extracellular acidification rate (ECAR),
a surrogate index of glycolysis (Fig. 26D). Collectively, these observations
corroborate our metabolic, biochemical, and anatomical measurements by
demonstrating directly that the adipose tissue of eNOS-TG mice maintains a
hypermetabolic state that could at least partially account for their increase in
whole-body oxygen consumption and resistance to obesity.

Discussion
The major findings of this study are that high fat diet results in the
downregulation of eNOS in adipose tissue and that overexpression of eNOS
124

Figure 25. Mitochondria are increased in the adipose tissue of eNOS-TG
mice. Measurements of mitochondria in epididymal adipose tissue and skeletal
muscle from WT and eNOS-TG mice: (A) Representative Western blots of
adipose tissue eNOS, PGC1α, ALDH2, COX4I1, and Sirt3; GAPDH was used as
a loading control. (B) Representative Western blots of skeletal muscle eNOS,
PGC1α, VDAC, COX4I1, and Sirt3. GAPDH was used as a loading control. (C)
Quantification of protein expression from panel A. (D) Quantification of protein
expression from panel B. n = 3 per group; *p<0.05 vs. WT; White bars, WT; blue
bars, TG. (E) Immunofluorescence images of adipose tissue sections from HFfed WT (panel i) and eNOS-TG (panel ii) mice; the sections were stained with
MitoID-Red as a qualitative index of mitochondrial mass. Scale bar=200 μM (F)
Representative photomicrograph of adipocytes isolated from HF-fed WT and
eNOS-TG mice (600,000 adipocytes per well). (G) mRNA analysis of Ppara and
Pparg. White bars, WT LFD; blue bars, eNOS-TG LFD; white hatched bars, WT
HFD; blue hatched bars, eNOS-TG HFD; n=6 per group; *p<0.05 vs. indicated
groups.
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Figure 26. eNOS overexpression increases adipose tissue mitochondrial
energetics. Extracellular flux (XF) analysis of adipose tissue explants from WT
and eNOS-TG mice fed a HFD for 14 wks: (A) Representative photomicrographs
of adipose tissue explants used for XF analysis; (B) Oxygen consumption rates
(OCR) of adipose tissue explants: After three baseline measurements, antimycin
A and rotenone (AA/Rot) were injected to identify the mitochondria-dependent
OCR. (C) Mitochondrial OCR calculated from measurements in panel B. (D)
Extracellular acidification rate (ECAR) measured from adipose explants; ECAR is
a surrogate measure of glycolytic rate. n = 3–4 per group, *p<0.05 vs WT.
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prevents diet-induced obesity. These findings support a causal role of eNOS in
regulating obesity and whole-body metabolism.

Our results suggest that the

mechanism of this anti-obesogenic effect of eNOS is related to an increase in
whole-body oxygen consumption associated with increased mitochondrial
abundance and activity in the adipose tissue. Collectively, these observations
support the notion that NO is an important regulator of adipocyte metabolism and
thereby weight gain due to a high fat diet. While it has been shown before that
deletion of eNOS gives rise to features of metabolic syndrome

336

, the rescue of

the obese phenotype by increasing eNOS indicates that enhancing eNOS
expression can overcome the metabolic changes caused by consumption of high
fat diet.
Several lines of evidence gathered during this study support the view that
the anti-obesogenic effects of eNOS are due to favorable changes in adipocyte
metabolism. Although on the basis of current results we cannot rule out, or even
fully assess all potential systemic effects, our observations that food
consumption, activity, plasma levels of cholesterol, leptin and thyroid hormones
were not different between WT and TG mice argue against a global, systemic
change that could completely account for the lean phenotype of the TG mice.
Both insulin resistance and obesity are complex phenotypes that are regulated
by multiple interactions between several tissues, some or all of which might be
affected in a manner not captured by our current analysis. Nevertheless, in
regulating obesity, the adipose tissue appears to be a major target of eNOS. Our
gene-dosage studies show that despite a 4-fold increase in eNOS in the aorta,
129

diet-induced obesity was only marginally affected in eNOS hemizygous mice, in
which there was no increase in eNOS in adipose tissue. Only in homozygous
mice, in which eNOS was increased both in adipose tissue and aorta, did the
anti-obesogenic effects of eNOS become apparent. This association of the lean
phenotype with eNOS expression in adipose tissue supports the view that an
increase in NO in adipose depots may be required for the manifestation of the
anti-obesogenic effects of eNOS.
How does eNOS regulate adipose tissue metabolism? Our results suggest
that eNOS supports both mitochondrial biogenesis and metabolic activity.
Previous observations showing that β-oxidation is impaired in eNOS-null mice

337

and that dietary supplementation with the NO precursor nitrite reverses features
of metabolic syndrome in eNOS-null mice

363

are supportive of this concept.

Although AMP kinase (AMPK) has been shown to relate with NO levels

364, 365

,

we did not find an increase in the phosphorylation state of AMPK in adipose
tissue (Fig. 27). However, we did find elevated levels of several metabolites such
as

BCAAs

and

short-chain

acylcarnitines

(e.g.,

acetylcarnitine,

proprionylcarnitine) in the adipose tissue of TG mice that were indicative of high
metabolic activity. Interestingly, oral supplementation with proprionylcarnitine
reduces obesity and hyperinsulinemia in obese rats

366

, which at least partially

recapitulates the phenotype of eNOS-TG mice. We also found in the adipose
tissue of TG mice elevated levels of proteins such PGC-1α and Sirt3 and
increased expression of ppara and pparg that regulate mitochondrial activity,
fatty acid oxidation, and biogenesis

284, 358-362, 367, 368

. That the increase in these
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Figure 27. Western blot analysis of AMPK activation status. Mice were fed a
LFD or HFD for 6 weeks and P-AMPK and total AMPK abundance were
measured by western blotting. n = 3–4 per group
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proteins was functionally significant is reflected by our observations that
mitochondrial abundance and rates of fatty acid oxidation were higher in the
adipose tissue from eNOS-TG mice. On the basis of these observations, we
propose that high levels of eNOS lead to an increase in mitochondrial biogenesis
and stimulation of fatty acid oxidation. This establishes a state of heightened
metabolism that attenuates the obesogenic effects of high fat consumption.
Although our results show that eNOS overexpression increases adipose
tissue metabolism by increasing mitochondrial content and activity, metabolic
activity could also be affected by eNOS-dependent changes in oxygen
distribution. Hence, it is possible that adipocytes of eNOS-TG mice are better
perfused than those of WT mice. Such an increase in tissue perfusion could be
due to either regulatory effects on vascular tone
increase in angiogenesis

369

and O2 consumption370 or an

371

. Nevertheless, we found that capillary density was

unaffected by eNOS overexpression, as isolectin B4 staining per adipocyte and
VEGFR2 expression were similar between the groups (Fig. 28), suggesting that
an increase in angiogenesis is unlikely explain the lean phenotype of eNOS-TG
mice.
The metabolic role of eNOS, however, appears to be tissue-specific. We
found that high fat feeding decreased eNOS in the adipose tissue but not in the
heart or the skeletal muscle. Hence, we expected that overexpression of eNOS
would ameliorate adipose tissue hypertrophy without affecting high fat-induced
changes in other peripheral tissues. Data from eNOS-TG mice substantiated this
expectation. These results showed that high fat-induced changes in glucose
133

Figure 28. Overexpression of eNOS does not affect capillary density in
adipose tissue. Fluorescence images and markers of capillary density in
sections of epididymal adipose tissue isolated from WT or eNOS-TG mice fed a
LFD or HFD for 6 weeks: (A) Representative images of isolectin B4 (green)
staining. (B) Isolectin B4 staining quantified per adipocyte. n = 9 per group. (C)
VEGFR2 expression in adipose tissue. Density of the VEGFR2 bands were
normalized to amido black stain. n = 6 per group. Note: the apparent decrease in
isolectin staining in HFD groups from panel A relates to an increase in adipocyte
size relative to the LFD group.
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disposal were not different between WT and eNOS-TG mice indicating that whole
body glucose metabolism, which is regulated primarily by glucose uptake by the
skeletal muscle 372, was not related to changes in eNOS levels. Nevertheless, the
observation that despite their lean phenotype the TG mice develop insulin
resistance is significant because a lean phenotype characterized by the browning
of fat is usually associated with improved glucose tolerance

325, 373-375

. It is likely

that a decrease in eNOS is a critical event in adipose tissue but not skeletal
muscle, and therefore, elevated levels of eNOS in the adipose tissue prevent
obesity without affecting systemic insulin resistance.
Results showing that overexpression of eNOS prevents obesity without
affecting insulin resistance also suggest that the two symptoms of metabolic
syndrome could be dissociated from one another. Similar segregation between
obesity and insulin resistance has been described previously. For instance, it has
been shown that overexpression of adiponectin completely rescues the diabetic
phenotype of ob/ob mice while promoting morbid obesity
observations that decreasing inflammation

377-379

376

. Moreover, the

does not result in lower

adiposity but improves insulin sensitivity, and that PPAR agonists decrease
insulin resistance but increase weight gain

333

provide additional support that

obesity and diabetes are disconnected and, in some cases, even conflicting
events in the etiology of metabolic disease. However, it remains to be
established how eNOS prevents hyperinsulinemia as well as impacts other
processes that are associated with insulin resistance, such as inflammation. It is
currently believed that, due to excessive adipocyte expansion, hypoxia and
136

necrosis occur in adipose tissue, which in turn leads to the recruitment of
inflammatory cells

380, 381

. The resultant low-grade chronic inflammation is

proposed to establish a state of insulin resistance

382, 383

. However, the eNOS-TG

mice develop the anti-obesogenic phenotype far before macrophage infiltration,
inflammation, and insulin resistance in adipose tissue occur 155, 295.
It is important to note that the eNOS-TG mice did not display a
lipodystrophic phenotype. Lipodystrophy in humans and animal models generally
results in severe hypertriglyceridemia, hyperinsulinemia, and insulin resistance
384-386

. The eNOS-TG mice, however, show decreased triglycerides and were

protected from hyperinsulinemia despite developing diet-induced glucose
intolerance. The prevention of hyperinsulinemia does not appear to be due to a
pancreatic defect: baseline insulin levels were not significantly different from WT
mice (Table 2), the glucose tolerance test showed a normal profile (Fig. 18 and
19), and the pancreatic islets from eNOS-TG mice appeared unremarkable (Fig.
29). These observations raise the interesting possibility that hyperinsulinemia in
response to systemic insulin resistance may be in part regulated by the adipose
tissue, although additional work is required to fully understand this relationship.
Additional investigations will also be required to assess how high fat diet
affects eNOS activity and expression. Although it has been shown that eNOS
levels are suppressed in high fat diet in part due to TNF--dependent
mechanisms

161

, the effects of diet on eNOS protein and activity are less clear.

The eNOS protein is subject to several post-translational modifications including

137

Figure 29. Hematoxylin and eosin-stained images of pancreas from WT and
eNOS-TG mice. Representative photomicrographs of pancreas isolated from
WT and eNOS-TG mice fed a HFD for 6 weeks; ×20 magnification.
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phosphorylation

387

, O-GlcNAcylation

388

, S-glutathiolation

253

, and acylation

389,

390

. In addition, the enzyme could also be uncoupled and therefore generate

superoxide instead of synthesizing NO. Interestingly, we found that while eNOS
monomer abundance was maintained in eNOS-TG mice (Fig. 30), the
phosphorylation of eNOS at Ser1177 and abundance of the eNOS dimer were
significantly decreased in both WT and TG mice fed a high fat diet (Fig. 30).
Although these changes in the eNOS-TG mice might be compensated by
continually elevated levels of eNOS protein, as evidenced by persistently
elevated citrulline levels (Fig. 15A,B), such changes in WT mice might result in a
chronic state of NO deficiency. Moreover, uncoupling of the enzyme could lead to
increased superoxide production and the formation of the toxic metabolite
peroxynitrite. Indeed, we found increased nitrotyrosine formation in adipose
tissue of high fat-fed mice (Fig. 31), although this was not significantly affected by
eNOS overexpression. Hence, in future studies it will be important to identify the
processes that regulate eNOS activity and how they might be involved in the
development of diet-induced obesity and insulin resistance.
In conclusion, the present study shows that preventing eNOS depletion by
forced expression of the eNOS transgene attenuates diet-induced obesity in
mice, without ameliorating systemic insulin resistance. These findings reveal a
novel anti-obesogenic role of eNOS and are consistent with the notion that eNOS
prevents weight gain in high fat-fed mice by stimulating mitochondrial biogenesis
and activity in adipose tissues. Further understanding of this role of eNOS could
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Figure 30. Analysis of eNOS expression and modification. Immunoblotting of
eNOS enzyme states that reflect eNOS activity state: WT and eNOS-TG (TG)
mice were fed a LFD or HFD for 6 weeks and eNOS abundance and
phosphorylation status were examined by immunoblotting. (A) Representative
Western blots of eNOS dimer, Ser

1177

phosphorylation of eNOS (P-eNOS), and

the eNOS monomer; (B) Quantification of P-eNOS; (C) Quantification of the
#

eNOS dimer; n = 3–4 per group; *p<0.05 vs WT LFD; p<0.05 vs. TG LFD.
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Figure 31. High fat feeding increases protein-nitrotyrosine adducts in
adipose tissue. Immunofluorescence images and quantification of nitrotyrosine
adducts in adipose tissue: WT and eNOS-TG mice were fed a LFD or HFD for 6
weeks. The adipose tissue was stained for nitrotyrosine adducts, and the adducts
were visualized by fluorescence microscopy. (A) Negative (–) and positive (+)
controls for nitrotyrosine staining. (B) Representative images of nitrotyrosine
staining in WT and eNOS-TG mice fed a LFD or HFD. (C) Quantification of
nitrotyrosine adducts from adipose tissues.
indicated group.
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n = 3 per group; *p<0.05 vs.
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lead to the development of new therapeutic modalities for preventing obesity and
weight gain in human populations.
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CHAPTER IV
REGULATION OF S.STEMIC METABOLISM B. NITRIC OXIDE

Introduction
Our previous work shows that overexpression of eNOS in mice regulates
diet-induced obesity, in part by increasing total body energy expenditure. This
resistance to obesity in eNOS transgenic mice is associated with the presence of
a more “brown-like” adipocyte in white adipose tissue depots, suggesting that
eNOS-induced changes in adipose tissue could underlie the anti-obesogenic
effects of eNOS. However, in rodents, adipocytes utilize less energy compared to
other peripheral tissues such as liver and skeletal muscle, which have estimated
metabolic rates 50 and 3 times that of adipose tissue, respectively
collectively account for at least 50% of the overall oxygen use

391

, and they

392

. To understand

the role of eNOS in regulating adipose tissue energy consumption and systemic
energy expenditure, we estimated the proportion of whole body oxygen
consumption that could be ascribed to adipose tissue.
To estimate the contribution of adipose tissue consumption, whole body
VO2 values and adipose tissue oxygen consumption rates were measured. Using
the Ideal Gas Law: (pV = nRT), where p is pressure of the gas, V is volume of the
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gas, n is number of moles of the gas, R is the universal gas constant, and T is
temperature in Kelvin, the number of moles of O2 consumed was calculated. The
VO2 in wild type (WT) mice was 6.622 L O2/h/kg (Chapter III, Fig. 16I). Assuming
an average body weight of ~40 g per mouse, this corresponds to 0.26 L
O2/h/mouse, which is equivalent to

250 mmols O2/day/mouse. Body fat

percentage, as measured by dual X-ray absorptiometry, was approximately 30%
(12.03 g fat) in the high fat-fed WT mice (Chapter III, Fig 16F). From adipose
tissue explant respirometry, we calculated the mitochondrial oxygen consumption
rate of adipose tissue explants from WT high fat-fed mice to be 21.94 pmols
O2/min/mg tissue (Chapter III, Fig 26C). Therefore, 12,030 mg of adipose tissue
consuming oxygen at a rate of 21.94 pmol/min/mg tissue is approximately equal
to 263,938.2 pmols O2/min and 0.380 mmols O2/day. Thus, dividing the adipose
explant value (0.380 mmols O2/day) by the whole body value (250 mmols
O2/day/mouse) suggests that approximately 0.15% of the total O2 consumption
per day is accounted for by adipose tissue in a WT mouse. When the same
calculation was applied to eNOS-TG mice, 0.18% of oxygen consumption is
attributed to adipose tissue; a difference of only 0.03% compared with WT mice.
These estimates suggest that an increase in adipose tissue mitochondrial
activity is unlikely to account for the anti-obesogenic phenotype of eNOS-TG
mice. The differences in standard metabolic rate between animals of different
body mass have been assessed to be due to proportional changes in the whole
of energy metabolism 393. It has been estimated that ~90% of mammalian oxygen
consumption in the standard state is due to mitochondrial activity of which ~80%
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is coupled to ATP synthesis

393

. Therefore, to assess the source of increased

energy expenditure in eNOS-TG mice a wider metabolic analysis is necessary.
The metabolic effects of nutrient excess extend beyond adipose tissue.
Indeed, the skeletal muscle of obese diabetic patients is characterized by fewer
and smaller-sized mitochondria

394, 395

, with decreased oxidative capacity

396

.

Moreover, high fat diet decreases the expression of genes involved in oxidative
phosphorylation and mitochondrial biogenesis of humans and mice

397

. In the

liver, it is associated with increased intracellular lipid accumulation

398-400

.

Mitochondrial abnormalities including ultrastructural lesions, depletion of mtDNA,
decreased activity of respiratory chain complexes

401

and impaired mitochondrial

β-oxidation have been found in patients with elevated hepatic lipid deposition

395,

402

, while increased expression or activity of hepatic fatty acid oxidation enzymes

reduces fat accumulation 403-406.
Metabolic dysfunction in peripheral tissue is likely to be reflected in the
plasma. Dysregulated fatty acid oxidation is characterized by increased plasma
levels of acylcarnitines in both obese and diabetic individuals
animal models of obesity and diabetes

407

as well as in

408

. Similarly, plasma lactate levels are

increased in individuals with severe diabetes

409

and levels of circulating FFAs

have been shown to be correlated with obesity and diabetes

410-412

. As a result,

metabolic changes in tissues other that the adipose depots could strongly
influence adiposity and thereby contribute to the metabolic phenotype of eNOSTG mice. Hence, identifying the specific metabolic pathways affected is therefore
important understanding the mechanism(s) by which eNOS prevents obesity.
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Recent advances in metabolomics have been critical for understanding
the systemic effects of metabolic diseases like obesity and diabetes

413

. By

measuring and, in some cases, mathematically modelling, changes in
metabolites found in biological fluids and tissues, metabolomic data can provide
key information on metabolic changes required to link phenotype to genetics

414,

415

. In particular, biological fluids such as plasma and urine can be used to

identify metabolic pathways that are perturbed by disease or impacted by drug
treatment or experimental intervention

416-419

. Interestingly, the idea of quantifying

changes in biological fluids as markers of disease is not a new one. Indeed,
there is evidence of such endeavors occurring as early as ancient Greece and
diagnostic 'urine charts' that linked the colors, smells and tastes of urine to
various medical conditions were widely used from the Middle Ages onwards

414

.

Metabonomics, and the related field of metabolomics, uses modern techniques to
analyse samples, but the basic principle of relating chemical patterns to biology
is the same. More recently, highly sensitive analytical techniques (i.e., mass
spectrometry,

nuclear

magnetic

resonance

spectroscopy)

applied

to

metabolomics and systems biology have emerged at the forefront of drug
discovery and understanding disease processes

420

.

Using a metabolomics approach, we examined plasma from WT and
eNOS-TG mice fed low or high fat diets to identify changes in systemic
metabolism caused by nutrient excess or eNOS overexpression. Our analysis,
was driven by three main questions: 1) How are plasma metabolites affected
by a high fat diet?; 2) What are the metabolic changes induced eNOS
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overexpression?; and 3) Which plasma metabolites are sensitive to both
high fat diet and eNOS? To address these questions we compared the
metabolite profiles of each group of animals and identified the metabolic
pathways most affected by diet and/or genotype.

Experimental Procedures
Animal studies: The C57BL/6J (wild-type; WT) mice were purchased from The
Jackson Laboratory (Bar Harbor, ME).

The eNOS-TG mice, which express

bovine eNOS under the control of the preproendothelin-1 promoter

338

, were

maintained on the C57BL/6J background. At 8 weeks of age, male mice were
placed on a 10% low fat diet (LFD; Research Diets, Inc., #D12450B), a 60% high
fat diet (HFD; Research Diets Inc., #D12492) or a custom formulated 60% high
fat diet containing GW4064 and maintained for 6 additional weeks. The custom
GW4064 diet was produced by Research Diets Inc. and was formulated by
adding GW4064 (Sigma, #G5172) to the HFD (#D12492) at a concentration of
180 mg of compound/kg of diet. Water and diet were provided ad libitum. Body
weights were recorded weekly. During the 7th week of feeding, body composition
analysis and glucose and insulin tolerance tests were performed. All other
variables were evaluated after euthanasia. All procedures were approved by the
University of Louisville Institutional Animal Care and Use Committee.
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Glucose and insulin tolerance tests: As described previously 339, glucose
tolerance tests were performed following a 6 h fast by injection (i.p.) of D-glucose
(1 mg/g) in sterile saline. Insulin tolerance tests were performed on nonfasted
animals by i.p. injection of 1.5 U/kg Humulin R (Eli Lilly, Indianapolis, IN).

Body composition: Body composition was measured by dual-energy X-ray
absorptiometry (Dexascan) using a mouse densitometer (PIXImus2; Lunar,
Madison, WI).

Metabolomic analysis of plasma: Whole blood was collected from WT and
eNOS-TG mice fed a LFD or HFD for 6 weeks by cardiac ventricular puncture
following a 16 hour fast. EDTA was added to whole blood samples to prevent
coagulation and plasma was separated from red blood cells by centrifugation.
Samples were shipped to Metabolon, Inc. (Durham, NC) for analysis. Metabolites
were extracted with methanol and relative metabolite abundance was measured
by GC/MS or LC/MS/MS exactly as described before

286

. Metabolites with

missing values were imputed by replacing missing values with half of the
minimum positive value in the original data. Metabolites with greater than 57% of
the values missing were omitted from the analysis. After a generalized logarithm
transformation, the data were autoscaled, i.e., mean-centered and divided by the
standard deviation of each variable. This step was performed to transform the
intensity values so that the distribution was more Gaussian. Values between
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groups were then compared using t-tests.

Univariate (e.g., volcano plots),

multivariate (e.g., PLS-DA), cluster (heatmap and dendogram), and Z-score
analyses were then performed. Z-scores were calculated using the equation:
; where

is the raw score,

is the mean of the population and

is the

standard deviation of the entire population. Most analyses were performed using
Metaboanalyst 2.0 software (http://www.metaboanalyst.ca/)

288

; Z-score plots

were constructed in GraphPad 5.0 software using data derived from volcano plot
analysis.

Statistical analyses: Data are presented as mean ± SEM. Multiple groups were
compared using one-way or two-way ANOVA, followed by Bonferroni post-tests.
Unpaired Student’s t test was used for direct comparisons. Statistical analyses
were performed with the program “R” http://cran.r-project.org/, Metaboanalyst
(http://www.metaboanalyst.ca/), and/or GraphPad 5.0. A P value less than 0.05
was considered significant.
Plasma bile acid measurements: Total bile acids were measured using a liquid
stable enzymatic colorimetric assay (Randox Laboratories, #BI3863) and
analyzed by a Cobas Mira Plus 5600 Autoanalyzer (Roche, Indianapolis, IN).

Results
Overexpression of eNOS prevents diet induced obesity. To examine the role
of eNOS in the regulation of systemic metabolism, mice overexpressing eNOS
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(eNOS-TG) and C57BL/6J (WT) mice were placed on a low fat diet (LFD) or high
fat diet (HFD) for six weeks. In agreement with our previous results, high fat-fed
eNOS-TG mice were protected against diet-induced obesity and gained 50% less
weight than high fat-fed WT mice (Fig. 32B). Dexascan analysis confirmed that
the body fat percentage of the eNOS-TG mice was significantly lower and lean
mass was significantly higher compared with WT mice after high fat feeding (Fig.
32C,D).

Plasma metabolomic analysis. To understand how overexpression of eNOS
prevents diet-induced obesity in mice in greater detail, we measured the relative
abundance of circulating metabolites in the plasma of WT and eNOS-TG mice on
low or high fat diets. This analysis led to the identification of 298 metabolites.
Using levels of these metabolites and excluding the genotype and diet group for
each animal (i.e., WT LFD), we performed a multivariate (PLS-DA) analysis of
the data. We found that group separation distance was significantly different
when groups were separated based on their given characteristic (genotype and
diet) rather than a randomly assigned variable. This indicates that the individuals
within each group are more similar to each other than if they were placed in any
other randomly assembled group.
After PLS-DA confirmed that the experimental animal groups were distinct,
we interrogated the differences in metabolite profiles between the groups. There
were 34 metabolites that were significantly different between low fat- and high
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Figure 32. Overexpression of eNOS prevents diet-induced obesity. Weight
gain and adiposity measurements from WT and eNOS-TG mice fed a low fat
(LFD) or high fat diet (HFD): (A) Body weights during 6 weeks of high or low fat
feeding, n = 7 per group; (B) Summarized weight gain over the course of 6
weeks of HF feeding, n = 7 per group; (C) Body fat percentage and (D) lean
mass percentage following 6 weeks of diet measured by Dexascan analysis. n =
7 per group; *p<0.05 and ***p<0.001 vs. indicated groups; #p<0.05 vs. WT HFD.
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fat-fed WT mice, 39 between low fat-fed WT and low fat-fed eNOS-TG mice, and
41 between high fat-fed WT and high fat-fed eNOS-TG mice. However, each of
these metabolites may not have been unique to only one comparison of animal
groups. For instance, of the 34 metabolites that were significantly different
between the low fat- and high fat-fed WT mice, 8 were also significantly different
between the low fat-fed WT and low fat-fed eNOS-TG groups. Further, 10 of the
34 metabolites that were significantly different between low fat- and high fat-fed
WT mice were also significantly different between the high fat-fed WT and eNOSTG groups. Finally, 3 metabolites were significantly different in each comparison
between the groups. This is illustrated by the Euler diagram in Figure 33 with
each comparison between animal groups represented by a separate oval. The
number of significantly different metabolites between these groups is in
parentheses. In the regions where the ovals overlap, the number represents the
number of metabolites that are shared between those comparisons of different
animals.

Plasma metabolic changes due to diet. As stated above, of the 298
metabolites identified, 34 were significantly different between the low and high
fat-fed WT mice. Volcano plot analysis showed that 12 of these metabolites were
increased and 22 were decreased after high fat feeding (Fig. 34A). To delineate
the biological relationships between metabolites that changed, we used the
MetPA tool of Metaboanalyst 2.0 for pathway analysis. Pathways were calculated
as the sum of the importance measures of the matched metabolites normalized
156

Figure 33. Changes in the plasma metabolome due to high fat feeding or
eNOS overexpression. Euler diagram showing the set-theoretic relationships
between WT and eNOS-TG mice fed a low fat (LFD) or high fat diet (HFD). Total
number of significantly different metabolites between the groups is shown in
parentheses. Number of significantly different metabolites shared between
groups is in the overlapping region of the corresponding groups. Diagram
constructed using Euler APE v3 software. n = 7 per group, total n = 21.
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by the sum of the importance measures of all metabolites in each pathway

288

.

The highest pathway impact value was related to branched chain amino acid
(BCAA)

biosynthesis

(i.e.,

valine,

leucine

and

isoleucine)

while

glycerophospholipid metabolism and glyoxalate and dicarboxylate metabolism
were also elevated. The pathway with the highest statistical significance was
primary bile acid synthesis (Fig. 34B).
A Z-score analysis was then performed and metabolites that were
significantly changed by more than 60% were plotted (Fig. 35). Metabolites that
were lower in the high fat-fed group were mostly lipids (lysolipids and long chain
fatty

acids).

Dicarboxylic

fatty

acids

(decanedioate,

tetradecanedioate,

hexadecanedioate and octadecanedioate) also were lower in high fat-fed mice.
Additionally, 1,5-anhydroglucitol (a marker of glycemic control) and members of
the bile acid metabolism pathway (β-muricholate, cholate, taurocholate) were
reduced. Sphingolipids (palmtioyl sphingomyelin and stearoyl sphingomyelin)
and markers of cysteine metabolism (S-methylcysteine and cystine) were among
the metabolites that were increased.

Plasma metabolic changes due to genotype. To delineate the systemic
metabolic changes that are induced by eNOS overexpression, similar analyses
as described above were performed on the 39 metabolites that were significantly
different between the low fat-fed WT and eNOS-TG mice. Volcano plot analysis
identified that 13 metabolites were increased and 26 decreased in the eNOS-TG
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Figure 34. Plasma metabolic changes due to diet. Metabolomic analyses of
plasma from WT mice fed a low fat (LFD) or high fat diet (HFD) for 6 weeks: (A)
Univariate analysis: Volcano plot of metabolites. Those metabolites that
significantly increased are in the quadrant on the right side of the plot and those
that significantly decreased are on the left (p<0.05, t-test); (D) Metabolites found
to be significantly different were subjected to pathway impact analysis using
Metaboanalyst MetPA and the Mus musculus pathway library. Fisher’s exact test
was used for overrepresentation analysis, and relative betweenness centrality
was used for pathway topology analysis. n = 14 animals: 7 WT LFD and 7 WT
HFD
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Figure 35. Z-score plot analysis of metabolite changes in plasma from low
and high fat-fed mice. WT mice were fed a low fat (LFD) or high fat diet (HFD)
for 6 weeks. Data are shown as standard deviations from the mean of LFD. Only
metabolites that increased significantly and those that decreased by >60% are
shown. Each point represents one metabolite in one sample. The color of
metabolite indicates the superpathway to which it belongs: green - lipid
metabolism; blue - bile acid metabolism; red - BCAA metabolism. n = 7 per
group.
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compared with the WT mice (Fig. 36A). Metabolic pathway analysis (Fig. 36B)
showed that -linolenic acid metabolism had a very high pathway impact value
and was highly significant. Other significant pathways were BCAA metabolism,
glycerophospholipid metabolism, pantothenate and CoA biosynthesis and lysine
metabolism.
In the eNOS overexpressing mice several markers of BCAA metabolism
(isovalerylcarnitine,

propionylcarnitine,

isobutyrylcarnitine,

and

4-methyl-2-

oxopentanoate) and bile acid metabolism (taurodeoxycholate, deoxycholate, and
cholate) were significantly increased as shown in the Z-score plot (Fig. 37).
Lysolipids and long chain fatty acids were decreased in the low fat-fed eNOS-TG
compared with low fat-fed WT mice.
Metabolic changes in high fat-fed WT and eNOS-TG mice were also
considered. Between groups there were 41 metabolites that were significantly
different; as determined by volcano plot analysis, 28 were increased in the
eNOS-TG mice while 13 decreased (Fig. 38A). After metabolic pathway analysis
was performed (Fig. 38B) three pathways were found to have both high pathway
impact values and significance: -linolenic acid metabolism, BCAA biosynthesis,
and ubiquinone and terpenoid biosynthesis. Other significant pathways were
arginine and proline metabolism, bile acid biosynthesis, histidine metabolism and
β-alanine metabolism.
Similar to the metabolic changes in low fat-fed eNOS-TG mice, markers of
bile acid metabolism (β-muricholate, cholate, deoxycholate, taurocholate,
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Figure 36. Plasma metabolic changes due to genotype. Metabolomic
analyses of plasma from WT and eNOS-TG mice fed a low fat diet (LFD) for 6
weeks: (A) Univariate analysis: Volcano plot of metabolites. Those metabolites
that significantly increased are in the quadrant on the right side of the plot and
those that significantly decreased are on the left (p<0.05, t-test); (D) The
metabolites found to be significantly different were subjected to pathway impact
analysis using Metaboanalyst MetPA and the Mus musculus pathway library.
Fisher’s exact test was used for overrepresentation analysis, and relative
betweenness centrality was used for pathway topology analysis. n = 14 animals:
7 WT LFD and 7 eNOS-TG LFD
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Figure 37. Z-score plot analysis of metabolite changes in plasma from low
fat-fed WT and eNOS-TG mice. WT and eNOS-TG mice were fed a low fat diet
(LFD) for 6 weeks. Data are shown as standard deviations from the mean of WT
LFD. Only metabolites that increased significantly and those that decreased by
>60% are shown. Each point represents one metabolite in one sample. The color
of metabolite indicates the superpathway to which it belongs: green - lipid
metabolism; blue - bile acid metabolism; red - BCAA metabolism. n = 7 per
group.
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Figure 38. Plasma metabolic changes due to genotype in obesity.
Metabolomic analyses of plasma from WT and eNOS-TG mice fed a high fat diet
(HFD) for 6 weeks: (A) Univariate analysis: Volcano plot of metabolites.
Metabolites that significantly increased are in the quadrant on the right side of the
plot and those that significantly decreased are on the left (p<0.05, t-test); (D)
Metabolites found to be significantly different were subjected to pathway impact
analysis using Metaboanalyst MetPA and the Mus musculus pathway library.
Fisher’s exact test was used for overrepresentation analysis, and relative
betweenness centrality was used for pathway topology analysis. n = 14 animals:
7 WT HFD and 7 eNOS-TG HFD.
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taurodeoxycholate
(isovalerylcarnitine,

and

taurochenodeoxycholate)

isobutyrylcarnitine,

and

BCAA

propionylcarnitine,

metabolism

N-acetylleucine,

leucine and valine) were significantly elevated in eNOS-TG compared with WT
mice on a high fat diet (Fig. 39). Phenylalanine and tyrosine metabolism and urea
cycle intermediates were also significantly elevated. Levels of long chain fatty
acids, lysolipids, and essential fatty acids were major metabolites that were lower
in the high fat-fed eNOS-TG compared with WT mice.

Plasma metabolic changes due to diet and genotype. To visualize the
metabolic changes more likely to be involved in eNOS-induced resistance to dietinduced obesity, we identified those metabolic changes occurring in HF-fed WT
mice that were reversed by eNOS overexpression. For this we plotted the Zscores of plasma metabolites found to be significantly different between WT LFD
and WT HFD mice (as in Fig. 35) and then superimposed the Z-scores from
eNOS-TG mice (Fig. 40). Although most metabolites were affected similarly by
HFD

in

both

gentoypes,

3-dehydrocarnitine,

3-indoxyl

sulfate,

cholate,

taurocholate, and leucine were significantly decreased by HFD in WT mice but
were comparatively higher in high fat-fed eNOS-TG mice. This could indicate that
the metabolic pathways to which they belong may be important in the mechanism
by which eNOS overexpression protects from diet-induced obesity and adiposity.
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Figure 39. Z-score plot analysis of metabolite changes in plasma from high
fat-fed WT and eNOS-TG mice. WT and eNOS-TG mice were fed a high fat diet
(HFD) for 6 weeks. Data are shown as standard deviations from the mean of WT
HFD. Only metabolites that increased significantly and those that decreased by
>60% are shown. Each point represents one metabolite in one sample. The color
of metabolite indicates the superpathway to which it belongs: green - lipid
metabolism; blue - bile acid metabolism; red - BCAA metabolism. n = 7 per
group.
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Figure 40. Modified Z-score plot analysis of metabolite changes in plasma
from low fat-fed WT and both high fat-fed WT and eNOS-TG mice. WT mice
were fed a low fat (LFD) or high fat diet (HFD) and eNOS-TG mice were fed a
HFD for 6 weeks. Data are shown as standard deviations from the mean of WT
LFD. Metabolites that increased significantly and those that decreased by >60%
between the WT LFD and HFD (black circles) are shown. Levels of those
metabolites were then compared between WT LFD and eNOS-TG HFD and
plotted (blue circles). Each point represents one metabolite in one sample. n = 7
per group.

174

175

Changes in bile acids and fatty acids are induced by diet and eNOS
overexpression.

Analyses

described

above

suggested

that

metabolism, which can regulate energy expenditure and obesity

bile

acid

421, 422

, and

carnitine metabolism, which is involved in regulating fatty acid oxidation, might be
significant pathways contributing to eNOS-induced resistance to obesity.
Therefore, to obtain additional insights into these metabolic changes, we plotted
changes in bile acids and fatty acid metabolism. In WT mice, HFD significantly
decreased 5 of the 7 bile acids compared with WT, low fat-fed mice (dotted line,
Fig. 41A). In the context of LFD, eNOS overexpression was associated with
higher levels of three of the bile acids compared with WT (Fig. 41A). On HFD,
eNOS-TG mice had significantly higher levels of all but one bile acid compared
with high fat-fed WT mice (Fig. 41A). When compared with WT LFD mice, levels
of bile acids were not significantly different in eNOS-TG mice fed a HFD, with the
marked

exception

of

deoxycholate

and

taurodeoxycholate

which

were

significantly elevated.
Bile acid signaling has been linked to increased fatty acid oxidation by increased
PPAR

423

and PDK-4

424

expression in liver. Our previous metabolic pathway

analyses showed that -linolenic acid metabolism had the highest pathway
impact and statistical significance of any pathway in eNOS-TG mice when
compared to WT on both diets (Fig 36B and 38B). Together these results led us
to investigate if levels of markers of fatty acid metabolism mirrored those of bile
acids. Indeed, medium-chain, long-chain, and essential fatty acids were
decreased in eNOS-TG mice when compared with WT on both LFD (data not
176

Figure 41. Changes in bile acid and fatty acid levels induced by diet and
eNOS overexpression. Plasma levels of (A) bile acids obtained from
metabolomics analyses from WT mice fed a high fat diet (HFD) (white hatched
bars) or eNOS-TG mice fed a low fat diet (LFD) (blue bars) or HFD (blue hatched
bars) for 6 weeks. n = 7 per group; *p<0.05, **p<0.01 and ***p<0.001 vs. WT of
same diet; #p<0.001 vs. WT LFD. (B) Plasma levels of fatty acids from HFD-fed
WT (white bars) and eNOS-TG (blue bars) mice. Data are expressed as fold
change vs. WT HFD. n = 7 per group, *p<0.05 vs. WT HFD.
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shown) and HFD (Fig. 41B). A majority of fatty acid species that were not
significantly decreased were either saturated fats with an odd numbered chain
length or polyunsaturated fats. These data suggest that eNOS overexpression
increases bile acid synthesis, which could increase the oxidation of fatty acids
and augment overall energy expenditure

Preventing bile acid synthesis does not prevent diet-induced obesity. To
test whether the lean phenotype of eNOS-TG mice is due to eNOS-induced
changes in bile acid metabolism, eNOS-TG mice were placed on a HFD for 6
weeks along with a synthetic inhibitor of bile acid synthesis, GW4064, which is a
farensoid X receptor (FXR) agonist that decreases bile acid biosynthesis and bile
acid pool size in C57BL/6J mice

421

. We reasoned that if bile acids are

responsible for the lean phenotype of eNOS-TG mice, decreasing their synthesis
should increase weight gain. Treatment of eNOS-TG mice with the bile acid
inhibitor showed a trend toward decreased levels of circulating bile acids (Fig.
42B), however there was no difference in weight gain compared with those fed
HFD alone (Fig. 42A). Likewise, glucose tolerance, insulin sensitivity and fasting
blood glucose levels were unaffected by the GW4064 supplementation (Fig. 42Ci-iii). These findings indicate that eNOS overexpression increases systemic
energy expenditure by a bile acid-independent mechanism.
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Figure 42. Preventing bile acid synthesis does not prevent diet-induced
obesity. eNOS-TG mice were fed a high fat diet (HFD) with or without GW4064
for 6 weeks. Body weight gain, glucose tolerance and insulin sensitivity were
examined: (A) Body weight gain by week of HFD. n = 5-6 per group; (B) Levels
of plasma bile acids. n = 4-6 per group; (C) Glucose tolerance test (GTT) area
under the curve (AUC), insulin tolerance test (ITT) AUC and fasting blood
glucose levels are shown. n = 5-6 per group.
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Discussion
The major goal of this study was to identify systemic metabolic changes
that could underlie the lean phenotype induced by eNOS overexpression. During
this analysis we considered that eNOS overexpression could either prevent a
defect caused by high fat feeding or increase metabolic pathways that would
otherwise promote resistance to obesity. Using metabolomics analysis, we
identified several metabolic pathways that were significantly affected by high fat
feeding or overexpression of eNOS. We found that, bile acid metabolites were
significantly decreased by high fat feeding and significantly elevated due to
eNOS overexpression. Additionally, after high fat feeding, bile acids remained
significantly elevated in eNOS-TG compared to WT mice. This indicated that
eNOS protects from a diet-induced suppression of bile acid metabolism and may
play a role in the resistance to obesity observed in eNOS-TG mice. We also
found evidence of significantly increased fatty acid metabolism in eNOS-TG
mice. Therefore, we hypothesized that eNOS overexpression stimulates bile acid
synthesis, which in turn increases both fatty acid oxidation and energy
expenditure, providing intrinsic resistance to diet-induced obesity. If this were
true, we reasoned that inhibiting bile acid synthesis would cause an accentuated
weight gain in eNOS-TG mice on a HFD. Alternatively, bile acid-independent,
eNOS-dependent changes in fatty acid metabolism could be important for the
maintenance of a lean phenotype.
To understand how eNOS overexpression induces a lean phenotype
during nutrient excess, we first investigated the systemic metabolic changes that
182

occur in WT mice on a HFD. Metabolomic analyses showed several metabolic
pathways affected in obesity. Primarily, HFD altered fatty acid and lipid
metabolism (mainly lysophospholipid and sphingolipids), bile acid metabolism,
glucose and cholesterol metabolism and markers of oxidative stress.
Lysophospholipid metabolism and its role in the regulation of obesity and
systemic metabolism are unclear. The term 'lysophospholipid' (LPL) refers to any
phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free
alcohol at either the sn-1 or sn-2 position. The prefix 'lyso-' derives from the early
observations that LPLs were hemolytic, however, it is now used to refer generally
to phospholipids missing an acyl chain. Lysophosphatidylcholine (lysoPC) is
found in small amounts in most tissues and is formed by hydrolysis of
phosphatidylcholine by the enzyme phospholipase A2, as part of the deacylation/re-acylation cycle that controls its overall molecular composition

425

. In

plasma, significant amounts of lysoPC are formed by a specific enzyme system,
lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver

426

.

The enzyme catalyzes the transfer of the fatty acids of position sn-2 of
phosphatidylcholine to the free cholesterol in plasma, with formation of
cholesterol esters and lysoPC

427

. LPLs play a key role in lipid signaling by

binding to the LPL receptors (LPL-R)

428

. LPL-Rs are members of the G protein-

coupled receptor family of integral membrane proteins

429

. LysoPCs are known to

account for 5–20% of all phospholipids in the serum

430

and have been

suggested to be closely associated with endothelial dysfunction, oxidative stress,
inflammation, atherogenesis, and obesity 430.
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Since lysoPCs have a relatively short half-life, they are thought to be
metabolic intermediates that are produced during the formation or breakdown of
other lipids. LysoPCs can have different combinations of fatty acids of varying
lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing
16, 18 and 20 carbons are the most common. In our analysis, several species of
lysoPC, including lysoPC 16:1 and 18:1 were decreased while one, lysoPC 17:0,
was increased by HFD. These findings are in accordance with a previous study
that showed decreased levels of lysoPC 16:1 and 18:1, as well as lysoPC 14:0,
15:0, 16:0, 17:1, 18:2, 19:0, 20:1 and 20:4 while lysoPC 17:0, 18:0 and 18:3 were
increased in diet-induced obese mice

431

. Additional studies have shown

decreased serum levels of lysoPC 18:1 and increased lysoPCs 14:0 and 18:0 in
obese men

432

as well as increased lysoPC 18:0 in high fat-fed pigs

433

. While

there was an association between specific lysoPC species and obesity, further
study is needed to elucidate their role in regulation of body composition.
Decreased levels of lysoPCs measured in obesity could indicate a
decrease in the activity of the enzymes responsible for their esterification.
However, studies in mice lacking LCAT, the main generator of circulating
lysoPCs, demonstrate a resistance to diet-induced obesity and insulin
insensitivity

434

. Further, LDLR/LCAT double knockout mice, in addition to

remaining lean after high fat feeding, display ectopic depositions of brown
adipocytes in skeletal muscle

434

. Though phospholipids, generally, were

decreased in these mice, the authors did not specify as to their species.
Conversely, overexpression of LCAT in mice has been shown to increase plasma
184

HDL and markedly reduced VLDL, LDL and triglyceride levels, but offered no
protection from the development of diet-induced atherosclerosis

435

. While our

analysis is suggestive of a decreased synthesis of circulating lysoPCs by LCAT,
further examination of the activity and expression of the enzyme would be
necessary to determine the mechanism underlying these changes.
As in our previous analysis of adipose tissue, we found that the plasma
levels of sphingolipid metabolites were profoundly increased in obesity. Palmitoyl
sphingomyelin and stearoyl sphingomyelin were the most significantly increased
metabolites high and low fat-fed animals. As mentioned previously (Chapter II),
the breakdown of sphingomyelin could yield significant amounts of ceraminde,
which is a potent inhibitor of insulin signaling. Plasma ceramide levels are
elevated in obese individuals and correlate with the severity of insulin resistance
436

.
Carbohydrate metabolism and glucose handling were also altered by

HFD, specifically, glucose and mannose levels were elevated while 1,5anhydroglucitol (1,5-AG), an important marker of glycemic control

437

, was

significantly decreased. This evidence of disrupted glucose metabolism is
consistent with our previous data that six weeks of high fat feeding is sufficient to
induce glucose and insulin intolerance (Chapter II, Fig. 4).
Bile acids have been shown to be potent regulators of metabolism.
Synthesized from cholesterol in the liver, bile acids are secreted into the
intestines to aid in digestion, primarily fat emulsion

185

438

. Recently, new roles for

bile acids as important signaling molecules have also been described. Bile acid
signaling has been shown to augment energy expenditure
homeostasis

440, 441

439

, lipid and glucose

421

, and body composition

. Through its control of short

heterodimer partner (SHP) expression, FXR has been shown to downregulate
hepatic fatty acid and triglyceride synthesis

440

while bile acid supplementation

increased brown adipose tissue energy expenditure and prevented obesity and
insulin resistance in mice

439

. Conversely, decreasing bile acid pool size

worsened obesity and diabetes in high fat-fed mice 421. Further, there is evidence
supporting an NO-induced increase of bile acid synthesis. Perfusion of livers with
NO donors increased bile acid outflow

442, 443

while inhibition of NOS reduced the

biosynthesis of bile acids by inhibiting the activity of hepatic Cyp7A1 444, the ratelimiting enzyme in bile acid production

445

.

Bile acids can also increase

mitochondrial biogenesis. Through the binding and activation of the G-coupled
receptor, TGR-5, in brown adipose tissue and skeletal muscle, bile acids trigger a
signaling cascade that activates PGC-1, a master regulator of mitochondrial
biogenesis

439

. These data support the idea that increased bile acid synthesis in

eNOS-TG mice could have a significant impact on body composition and energy
expenditure.
The relationship of bile acids and triglyceride metabolism has been
established for decades

445

. In clinical trials, dyslipidemic patients given bile acid-

sequestering resins exhibited increased plasma triglyceride and VLDL levels

446,

447

. Additionally, patients with deficiencies in CYP7A1 are also characterized by

increased plasma triglyceride concentrations
186

448

. In rodent models, FXR

activation has been linked to lower plasma triglycerides
hepatic PPAR expression

440, 449

by the induction of

423

. In our analysis, overexpression of eNOS induced

a broad decrease in plasma FFA levels, predominantly long chain fatty acids and
essential fatty acids. Further, on HFD levels of the β-oxidation intermediates, 3hydroxyoctanoate and 3-hydroxydecanoate, were decreased while the carnitineconjugated end product, propionylcarnitine, was higher in eNOS-TG mice
compared with WT mice. Taken together, these data suggest that eNOS
overexpression increased β-oxidation and decreased fatty acid synthesis.
Studies in NO donor-treated rat hepatocytes showed similar results by
increasing β-oxidation in a cGMP-dependent manner and decreasing lipid
synthesis

450

. Additionally, inhibitors of NOS

hepatic lipid synthesis

451

and deletion of eNOS increased

452

. The eNOS KO mice also showed decreased

expression of genes involved in β-oxidation and increased expression of
neolipogenic genes in skeletal muscle

337

. Collectively, these data suggest that

eNOS regulates lipid metabolism, possibly via a PPAR-mediated mechanism
453

. As shown previously, PPAR was elevated in the adipose tissue of eNOS-

TG mice (Chapter III) which supports the hypothesis that eNOS overexpression
increases fatty oxidation capacity.
Because the liver is the site of both bile acid synthesis and fatty acid
metabolism, we hypothesized that eNOS overexpression increases bile acid
synthesis, and, in doing so, might increase fat utilization, either directly by
increasing PPARα activity in the liver, or indirectly, by promoting increased
thermogenesis in other peripheral tissues, such as brown adipose tissue.
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Activation of FXR by the synthetic agonist GW4064 was shown previously to be
sufficient to decrease bile acid levels and energy expenditure, thereby
accentuating diet-induced weight gain and insulin resistance

421

. However, in our

study, bile acid inhibition had no effect on weight gain, glucose handling or insulin
sensitivity in eNOS-TG mice.
These data appear to indicate that eNOS overexpression increases fatty
acid metabolism and systemic energy expenditure by a bile acid-independent
mechanism. The increase in PPAR expression measured in the adipose tissue
of eNOS-TG mice may indicate that eNOS overexpression has a direct effect on
PPAR-mediated increased fatty acid oxidation in other tissues as well. To
address this hypothesis, we plan to measure PPARα-driven genes in liver and
skeletal muscle. Should results suggest a role for PPARα, future experiments
would focus on pharmacological or genetic disruption of PPAR in the eNOS
overexpressing mice. For example, crossing PPAR knockout mice with eNOSTG mice and feeding a high fat diet could be an especially revealing experiment.
If these mice were to become obese as a result of high fat feeding we would
have strong evidence to support the claim that eNOS protects from obesity via a
PPAR-mediated mechanism. Additionally, activation of PPAR in WT mice
during high fat feeding could also be informative. Fibrates are a class of PPAR
agonists that have been used in combination with statins to lower plasma
cholesterol and triglycerides
macrovascular risk

455

454

and have been shown to reduce micro- and

. Fibrate treatment during high fat feeding of WT mice

188

would provide additional insights into the role of PPAR-induced fatty acid
metabolism on the development of metabolic disease.
Fibrates have also been shown to promote the catabolism of BCAAs

456

.

In our analysis, plasma levels of BCAAs and short-chain acyl carnitines were
decreased in high fat-fed WT mice and increased in the eNOS-TG mice, similar
to our previous findings in adipose tissue (Chapter III). It has been shown before
that plasma BCAAs are increased in obese and diabetic humans and rodents

66,

312

, but the significance of BCAAs in regulating adiposity or insulin resistance is

unclear. BCAAs have also been shown to promote insulin resistance

312

. Despite

lower levels of weight gain, rats fed a BCAA/HF diet remain insulin resistant.
Sustained insulin resistance in these rats has been linked to mTOR activation
which induces insulin resistance by phosphorylating IRS1

312

,

457, 458

.

BCAA supplementation has been shown to have favorable effects on dietinduced metabolic disease. Feeding leucine prevented obesity in rodents
and was associated with lower adiposity in humans

459, 460

,

461

, while isoleucine

decreased tissue TG accumulation and adiposity and increased expression of
PPAR and UCPs in diet-induce obese mice

462

. Additionally, increasing BCAA

levels by deletion of BCATm, the enzyme that catalyzes the first step in BCAA
metabolism, completely prevents HFD-induced insulin resistance and adiposity in
mice

311

.

Furthermore,

BCAAs

as

well

as

3C-acylcarnitines

mitochondrial biogenesis and promote energy expenditure

increase

311, 354-356

. Therefore, it

is possible that BCAA levels in high fat-fed eNOS-TG mice is due to increased
protein degradation and synthesis, which dissipates excess energy.
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Limitations of this study are inherent to the descriptive approach employed
by metabolomics analyses. Metabolomics is a powerful analytical tool to
interrogate wide-ranging changes in different experimental samples. However,
metabolomics analysis is designed mainly to generate new hypotheses as
opposed to test specific hypotheses. These analyses can be very useful in
nutritional research and biomarker discovery, but they give only a “snapshot” of
changes that are occurring at that moment. Furthermore, current libraries of
known metabolites and metabolic pathway models are incomplete. Nevertheless,
such approaches are indispensable for identifying novel pathways that might be
important to health and disease.
In summary, this study identified significantly altered metabolic pathways
due to high fat feeding and eNOS overexpression. Bile acid metabolism and fatty
acid metabolism pathways were significantly decreased by nutrient excess in WT
mice but were rescued by eNOS overexpression. Inhibiting bile acid synthesis
did not produce an obese phenotype in eNOS-TG mice on HFD; however, eNOS
shows a clear influence on fatty acid metabolism. Future studies will focus on the
mechanism(s) by which increased eNOS activity regulates fatty acid metabolism
and energy expenditure.
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CHAPTER V
CONCLUDING DISCUSSION

We undertook the studies presented here were to develop a better
understanding of how NO regulates metabolism. For this, we examined
metabolic changes that accompany diet-induced obesity and insulin resistance
and we assessed the impact of increasing NO during nutrient excess. Our
hypothesis was that increased NO derived from eNOS prevents dietinduced obesity by promoting adipose tissue browning and increasing
systemic metabolism. To address this hypothesis, we examined whether
overexpression of eNOS was sufficient to promote metabolic alterations in WAT
during high fat feeding that would prevent obesity and insulin resistance. To
obtain a more comprehensive view, we investigated changes in systemic
metabolism that were induced by eNOS.
As discussed in Chapter II, we first examined the metabolic and
bioenergetic changes occurring in WAT with obesity. After six weeks of high fat
feeding, metabolomic analyses showed marked changes in glycerolipid and
amino acid metabolism, with most metabolites showing a decrease in WAT of
obese mice. Levels of succinate, however, increased significantly in WAT from
high fat-fed mice, suggesting changes in mitochondrial metabolism. Furthermore,
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we

found

changes

indicative

of

mitochondrial

remodeling,

decreased

mitochondrial bioenergetic capacity and striking decreases in eNOS abundance.
Collectively, these results revealed a range of coordinated changes in
mitochondrial function that might be contributing to the “whitening” of adipose
tissue in obesity.
To examine the significance of in eNOS downregulation in WAT, we
investigated whether increasing eNOS expression would prevent obesity and its
metabolic consequences. In Chapter III, we present data showing that
endothelial-specific overexpression of eNOS prevents diet-induced obesity and
reduces plasma levels of insulin, TGs and FFAs, without affecting systemic
glucose intolerance. The eNOS-TG mice displayed a higher metabolic rate and
reduced adipocyte hypertrophy in WAT. Metabolomic analyses indicated an
increase in fatty acid oxidation in WAT that was reflected by an increase in the
expression levels of PPAR- and PPAR- genes, higher abundance of
mitochondrial proteins and increased rate of mitochondrial oxygen consumption.
These findings demonstrate that eNOS has anti-obesogenic effects that prevent
high fat diet-induced obesity without affecting systemic insulin resistance, in part
by stimulating metabolic activity in WAT.
Although effects of eNOS overexpression on WAT were quite profound,
we questioned whether these effects could account fully for the increase in
whole-body energy expenditure and the lean phenotype observed in eNOS-TG
mice. Therefore, as discussed in Chapter IV, we studied effects of eNOS
overexpression on systemic metabolism. Measurements of plasma metabolites in
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eNOS-TG mice were consistent with increases in fatty acid, bile acid and BCAA
metabolism. However, our experiments to decrease bile acids in eNOS-TG mice
did not markedly affect on body composition and glucose or insulin handling
suggesting that the metabolic effects of eNOS overexpression on fatty acid
metabolism are not mediated by bile acids. From these findings we propose that
eNOS increases BCAA metabolism thereby increasing PPAR activity in the liver
and possibly skeletal muscle leading to increased fat utilization. Further
elucidation of the regulatory effects of eNOS on BCAA metabolism and its effects
on fatty acid metabolism could help understand the mechanism by which eNOS
increases systemic energy expenditure and prevents adiposity.
Nevertheless, data obtained from studies so far support a pivotal role of
NO as a central regulator of energy metabolism and body composition. This
regulation, however, is inherently complex and growing evidence demonstrates
divergent effects of NO depending on its source and anatomic location. In the
sections that follow, our findings are discussed in the context of the known
interactions between NO, its sources of generation and obesity and insulin
resistance.

Regulation of obesity and insulin resistance by NO
In one approach, pharmacological studies as well as gain-of-function and
loss-of-function studies helped in elucidating the critical roles for NO in regulating
obesity and insulin resistance. Previously, supplementation with the NOS

193

substrate, L-arginine, and inhibition of NOSs were the most common
pharmacological approaches used to determine how NO regulates body
composition and insulin sensitivity. Genetic approaches, utilizing mice in which
components integral to the synthesis of NO have been deleted or overexpressed,
have led to further development of a model by which NO regulates systemic
metabolism. The model thus built is extensive in its complexity and integration
and involves nearly all aspects thought to be important in regulating metabolic
homeostasis.

Lessons from pharmacological interventions
Using primarily L-arginine and NOS inhibitors, early pharmacological
studies showed that NO is a potent regulator of both energy intake and
expenditure. Interestingly, both L-arginine and NOS inhibitors prevent obesity
and insulin resistance, albeit by different mechanisms.

nNOS-derived NO increases food intake
In rodents, L-arginine was shown to increase, and NOS inhibitors to
decrease, food intake

193, 463-466

. These effects were due to NO activity in the

brain, impinging on the leptin and serotonergic systems that regulate hunger.
Leptin, given intracranially, was found to diminish diencephalic NOS activity and
decrease food intake and body weight gain, and intracranial co-administration of
L-arginine antagonized this effect

467

. Furthermore, intracerebroventricular

injection of L-arginine, likely through stimulation of NOS activity, inhibited

194

serotonin-induced anorexia caused by IL-1β 468. Studies with NOS inhibitors have
further solidified our understanding of the central effects of NO on hunger.
Systemic administration of the NOS inhibitor, NG-nitro-L-arginine, reduced food
intake in obese rats and increased serotonin metabolism in the cortex,
diencephalon, and medulla pons, thereby implicating the central serotoninergic
system in mediating the anorexic effect of NOS inhibitors

469

. Other NOS

inhibitors, such as L-NAME, promote weight loss and diminish food intake in
ob/ob and db/db mice
insulin

sensitivity

in

465

and obese rats

high

fat-fed

470

and reduce adiposity and improve

mouse

models

471

.

Interestingly,

intracerebroventricular administration of NG-monomethyl-L-arginine (L-NMMA)
was shown also to regulate insulin secretion and peripheral insulin sensitivity

472

,

suggesting that centrally derived NO has effects that extend to distal nodes of
systemic metabolism.

It is also possible that this effect contributes to the

hyperphagic effects of NO, as insulin is well known to regulate hunger and satiety
473-477

. Taken together with numerous other studies demonstrating a role for NO

in the regulation of hunger

478-482

, it would appear that NO produced in the brain

antagonizes anorectic signals and stimulates food intake.

Evidence supporting a role of NO in energy expenditure and glucose and lipid
metabolism
Ostensibly, the reported anti-anorexic effects of NO might imply that by
promoting food intake, increased levels of NO, e.g., that elicited by
supplementation

with L-arginine,

should increase adiposity and insulin

195

resistance.

However, human studies have shown repeatedly that L-arginine

supplementation has favorable effects on body composition and insulin sensitivity
483-489

.

Results from animal studies are in agreement: in rodents, L-arginine

treatment has multimodal effects characterized by decreased fat mass, increased
muscle mass, and improved insulin sensitivity. Despite promoting hyperphagia,
L-arginine feeding reduced WAT mass, improved insulin sensitivity, and
increased energy expenditure in mice

490

. In rats, not only has dietary L-arginine

supplementation been shown to reduce fat mass, but it appears to increase
skeletal muscle and brown fat mass and reduce serum concentrations of
glucose, TGs, FFAs, homocysteine, dimethylarginines, and leptin as well

491, 492

.

Similar salubrious systemic effects of L-arginine have been demonstrated in pigs
493

. Overall, these collective data suggest that L-arginine, and by inference, NO,

has the capacity to reduce fat mass by increasing mitochondrial biogenesis,
regulating brown adipose tissue signaling, and increasing the expression of
genes that promote oxidation of energy substrates 494.
Chronic treatment with sildenafil, which prevents the degradation of cGMP
and is commonly prescribed to improve penile erectile function, improved insulin
action and diminished obesity in high fat-fed mice

495

. Shorter durations of

sildenafil treatment have been shown to promote “browning” of white adipose
tissue

496

. While there are no reports that type 5-phosphodiesterase inhibitors

such as sildenafil regulate obesity in humans, they have been shown to increase
mitochondrial biogenesis in human adipose tissue ex vivo
the potential to increase energy expenditure.
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497

, suggesting at least

Other drugs that affect NO production or function lend additional support
to a role for NO in regulating insulin sensitivity. Beraprost (a stable prostaglandin
analog) restores eNOS phosphorylation in endothelial-specific IRS-2 knockout
mice and has been found to rescue capillary recruitment and to promote
adequate insulin and glucose delivery to the skeletal muscle

217

.

Insulin, L-

arginine, and sodium nitroprusside, by promoting S-nitro(sy)lation of key proteins,
have been found to be particularly critical for regulating vascular endothelial
498

insulin uptake and its transendothelial transport

. Hence, NO derived from

eNOS appears play an important role in regulating systemic glucose metabolism
and insulin delivery to peripheral tissues.
A characteristic feature of NO signaling is that effects of NO depend on its
site of generation, concentration, and duration of application. Particularly
interesting are the modes of action of NO in the liver, skeletal muscle, and
pancreas. Although chronic treatment with NOS inhibitors promote weight loss
and insulin sensitivity in animal models

465, 470, 471

inhibitors causes systemic insulin resistance

, acute application of these

499

. This is mediated in part by

actions in the liver, which can regulate systemic responses to insulin

500

.

Administration of BH4, which is known to be oxidized to BH2 in the diabetic state
501-503

and plays an important role in regulating coupled eNOS activity (see

above), to STZ-induced diabetic mice lowered fasting blood glucose levels in an
eNOS-dependent manner and improved glucose tolerance and insulin sensitivity
in ob/ob mice

504

.

This metabolic improvement was at least partially due to

eNOS-mediated activation of AMPK in the liver, which suppressed hepatic
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gluconeogenesis

504

. Hence, eNOS uncoupling in liver may be important for

regulating systemic glucose metabolism.
Several studies demonstrate an important role of eNOS and nitrogen oxides
in the liver. For example, intraportal administration of NOS inhibitors was shown
to cause insulin resistance, which was rescued by intraportal delivery of the NO
and superoxide donor, SIN-1

505, 506

. Interestingly, when liver glutathione was

first depleted by buthionine sulfoximine, the effects could not be rescued by
sodium nitroprusside or SIN-1

506

. These results suggest that the formation of

nitrosated glutathione (GSNO) in the liver might be important in mediating
systemic responses to insulin. That intraportal delivery of glutathione methyl
ester and SIN-1 enhances insulin sensitivity in rats would appear to support this
view 507.

The NO-HISS connection?
How does NO (and its oxidation products) in the liver mediate systemic
responses to insulin? It has been suggested that the hepatic role of NO may
relate to a hormone called ‘hepatic insulin-sensitizing substance (HISS)’. This
substance, for which there are only suggestive candidates (e.g., bone
morphogenetic protein-9

508

), appears to account for 55% of the glucose disposal

by insulin. Briefly, it is posited that post-prandial elevations in insulin results in
release of a hormone, i.e., HISS, from the liver that acts on skeletal muscle to
promote glucose uptake

509, 510

. Intriguingly, one study suggests that HISS, not

insulin action, regulates the peripheral vasodilation generally attributed to insulin
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511

. Atropine or hepatic surgical denervation inhibited the peripheral vascular

actions of insulin, allegedly by blocking HISS release, whereas intraportal
delivery of acetylcholine, which increases NOS activity, restored HISS release
and insulin-mediated vasodilation

511

. These findings are consistent with original

studies showing that insulin-mediated vasodilation is dependent on NO

512, 513

and that insulin-mediated skeletal muscle vasodilation contributes to insulin
sensitivity in humans 514. Combined with other studies suggesting a role for NO in
promoting the release of HISS

515-517

, this suggests that the putative hormone

could be an NO-regulated, liver-produced, endocrine mediator of classical EDRF
crucial for glucose disposal. However, (in addition to the identity of HISS) it
remains unclear how this distally engendered mode of vasoregulation integrates
physiologically (and pathologically) with the local effects of insulin and NO in the
vasculature 214-217.

Pancreatic effects of NO
Extremely important for maintaining metabolic homeostasis, the pancreas
utilizes NO to regulate their function. The pancreas is comprised of two types of
glands: (1) exocrine glands, which secrete the bicarbonate and digestive
enzymes needed to neutralize the acidic gastric contents entering the small
intestine and to complete digestion of food, respectively; and (2) endocrine
glands, i.e., the islets of Langerhans, which contain several types of secretory
cells, including α cells, β cells, δ cells, and F cells. Each of these cell types
secretes multiple proteins, such as insulin (β cells), glucagon (α cells), and

199

somatostatin (δ cells). NO has been shown to affect both exocrine and endocrine
functions of the pancreas 518, 519.
With respect to insulin release, it appears that NO stimulates early, glucoseinduced insulin release, while it is responsible for cytokine (e.g., IL-1β)-mediated
inhibition of insulin secretion. This dual role of NO in regulating insulin secretion
has been a subject of controversy (e.g.,

520

), which may be, in part, due to the

mechanistic complexity regulating pancreatic insulin secretion; compounded by
the multiple actions of NO.

The inhibitory actions of NO on insulin release

appear to be due to iNOS-derived NO, which is implicated in the destruction of
islet cells in type 1 diabetes
stimulating effects of NO

521, 522

. However, mechanisms regulating the insulin-

523-526

have been more difficult to elucidate. NO has

been suggested to stimulate islet cell insulin secretion by inducing calcium
release from mitochondria

527

, which may be due to NO-mediated inhibition of

respiration and mitochondrial depolarization. Nevertheless, the stimulatory
effects of NO on insulin secretion are relatively subtle

526

, which might explain

why some studies suggest that NO is not involved in the initiation of insulin
secretion from pancreatic islets 528, 529.

Lessons from human studies and genetic interventions
Considerable data suggests an association between genetic polymorphisms
in NOS isoforms and insulin resistance. Notably, several studies have associated
a T(-786)C variant of the eNOS gene with insulin resistance

530-532

genetic variants in the eNOS locus are associated with T2D

533
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. Several other

, susceptibility for

insulin resistance, hypertriglyceridemia, and low HDL
endothelial function in individuals prone to T2D

534

, or worsened

535

. Polymorphisms in the iNOS

gene have been associated with higher plasma glucose and elevated waist/hip
ratios 536, and variants in the iNOS gene promoter are associated with T2D 537.
Genetic deletion, manipulation, and overexpression of NOS isoforms in mice
have allowed for interrogation of mechanisms by which NO regulates metabolic
health and disease. In mice, it has been reported that deletion of eNOS causes
insulin resistance, hyperlipidemia, and hypertension

336

. While full gene deletion

mimics human “metabolic syndrome,” even partial gene deletion of eNOS results
in exaggerated insulin resistance, glucose intolerance, and hypertension induced
by a high fat diet

538, 539

. Mice lacking all NOS isoforms, i.e., eNOS/nNOS/iNOS

triple knockout mice, demonstrate increased visceral obesity, hypertension,
hypertriglyceridemia, and impaired glucose tolerance, and, it is interesting to
note, that this is one of the few mouse strains to date to have spontaneous
myocardial infarctions, apparently due to unstable coronary arteriosclerotic
lesions
studies

540

. That NOS is important to insulin sensitivity was further shown by
in

mice

in

which

overexpression

of

dimethylarginine

dimethylaminohydrolase—an enzyme that catalyzes the breakdown of the
endogenous inhibitor of NOS, ADMA—increased insulin sensitivity 541.

Anti-obesogenic effects of eNOS
It appears that the metabolic phenotype elicited by insufficient levels of
eNOS-derived NO relates directly to defects in intermediary metabolism in key

201

peripheral tissues. Supporting evidence supplied by eNOS KO mice include a
markedly lower energy expenditure and decreases in mitochondrial content and
fatty acid oxidation in muscle compared with WT mice

337

eNOS KO mice demonstrate an impaired ability to exercise

; and, as expected,
542

. Gain-of-function

studies show a remarkable ability of eNOS to regulate body composition and
increase metabolism. Supplementation of eNOS KO mice with nitrate, which can
be serially reduced to nitrite and NO, decreases not only blood pressure, but
visceral fat and TGs as well, thus reversing features of metabolic syndrome

363

.

Furthermore, our studies show that mice overexpressing eNOS acquire an antiobesogenic phenotype characterized by resistance to accumulation of white
adipose tissue in response to a high fat diet, a higher metabolic rate, resistance
to diet-induced hyperinsulinemia, and remarkably lower plasma levels of FFAs
and TGs (Chapter III)

286

. Our findings were supported by results from an

investigation of an eNOS phosphomimetic point mutant mouse model that was
published shortly after our study

543, 544

. Mutation of serine 1176 of eNOS to an

aspartic acid resulted in increased endothelial NO production as well as
resistance to diet-induced weight gain and hyperinsulinemia; mutation of the
residue to an alanine, which cannot be phosphorylated, resulted in insulin
resistance and features of metabolic syndrome 195, 544.
How does eNOS regulate metabolism and body composition? Several
possibilities exist. Consistent changes in plasma lipids insinuate a central role of
eNOS in lipid oxidation or synthesis, e.g., eNOS KO mice have elevated plasma
levels TGs and FFAs compared with WT mice
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336, 539

, while eNOS transgenic

mice show diminished abundance of the lipids

160

. That these differences are

due to modulation of fat oxidation are suggested by studies showing a direct
effect of NO on the capacity to oxidize fat. Not only do eNOS KO mice show
diminished fat oxidation capacity in skeletal muscle

337

, but administration of a

NOS inhibitor is sufficient to increase serum TGs and diminish hepatic fatty acid
oxidation in rats
transferase

545

, potentially by decreasing the activity of carnitine palmitoyl

546

. Similar, NOS inhibitor-dependent decreases in fat oxidation

capacity have been found in heart 547. In isolated hepatocytes, treatment with NO
donors was shown to increase fatty acid oxidation in a cGMP-dependent manner
by inhibiting acetyl CoA carboxylase (thereby decreasing production of malonyl
CoA) and stimulating carnitine palmitoyl transferase activity 450. Interestingly, NO
also inhibits fatty acid synthesis in hepatocytes
studies showing that NOS inhibitors
lipid synthesis in liver

451

450

, which is consistent with

or genetic deletion of eNOS increases

452

. In skeletal muscle, genetic deletion of eNOS increases

neolipogenic genes expression while downregulating genes involved in βoxidation 337.
That genes involved in fatty acid oxidation are modulated by NO is
consistent with data showing that overexpression of eNOS increases the
expression of peroxisome proliferator activated receptor (PPAR)-α
well known to regulate lipid metabolism

160

, which is

453

. However, it is possible that NO

regulates fat oxidation post-translationally as well. Recent studies show
widespread

S-nitrosation

of

multiple

enzymes

involved

in

intermediary

metabolism. In particular, the liver enzyme, very long chain acyl-coA

203

dehydrogenase (VLCAD) was shown to be nitrosated at Cys238, which
increased the catalytic efficiency of the enzyme, and this modification was absent
in eNOS KO mice

548

. Collectively, these studies suggest that the powerful anti-

obesity effects of eNOS-derived NO could be due to simultaneous increases and
decreases in fat oxidation and a decrease in fat synthesis.

iNOS promotes insulin resistance
The iNOS enzyme also regulates systemic metabolism, particularly insulin
resistance. Although ablation of the iNOS gene has no effect on diet-induced
obesity, its absence was shown to improve glucose tolerance, normalize insulin
sensitivity, and prevent derangements in the PI3K/Akt signaling in response to
insulin

549

. Commonly, increases in iNOS expression in skeletal muscle of obese

mice are associated with increased S-nitrosation of the insulin receptor (IR), IRS1, and Akt, suggesting that nitrosative post-translational modifications of proteins
in the insulin signaling pathway are responsible for iNOS-induced insulin
resistance

550, 551

. The presence of iNOS appears to decrease the abundance of

IRS-1 by promoting its proteasomal degradation

186

. Interestingly, an acute bout

of exercise was sufficient to downregulate iNOS in high fat-fed rats as well as
prevent S-nitrosation of proteins involved in insulin
signaling, and administration of an inhibitor of iNOS (L-N6-(1-iminoethyl)lysine; LNIL) pheno-copied these effects
known treatments for diabetes

552

. Also, aspirin—which is one of the oldest

553, 554

insulin sensitivity in diabetic patients

and which improves blood glucose and

555

and animal models of T2D
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556

—inhibited

iNOS-mediated S-nitrosation of IR, IRS-1, and Akt in skeletal muscle and
improved insulin sensitivity 557.
Expression of iNOS in peripheral tissues other than skeletal muscle is also
important for regulating insulin sensitivity. Selective overexpression of iNOS in
liver is sufficient to cause hepatic insulin resistance, hyperglycemia and
hyperinsulinemia

558

, and the use of an iNOS-specific inhibitor (L-NIL) reversed

hyperglycemia, hyperinsulinemia, and insulin resistance in ob/ob mice

188

. In

obesity, proinflammatory macrophages accumulating in adipose tissue are
responsible for the majority of iNOS expression

189-191

inflammatory signaling implicated in insulin resistance

and may propagate the

168

. Importantly, the role of

iNOS in adipose tissue appears to differ remarkably from the canonical NOcGMP pathway, as high fat diet-induced increases in proinflammatory cytokines
and macrophage recruitment were attenuated by the administration of sildenafil
559

. Interestingly, lack of iNOS does not prevent age-induced insulin resistance

560

, which suggests that not all insulin resistant states are created equal

561

. In

agreement with this view it has been shown that mice lacking the nNOS isoform
are insulin resistant due to a sympathetic, alpha-adrenergic mechanism 562.
Integration of findings from these studies, and our own, helps to form a
model illustrating the complex role of NO in regulating obesity and insulin
resistance (Fig. 43). NO derived from eNOS appears to have both antiobesogenic and insulin-sensitizing properties. Its anti-obesogenic role stems
from its ability to increase fat oxidation in peripheral tissues such as skeletal
muscle, liver, and adipose tissue. As mentioned above, there is evidence that NO

205

also decreases lipid synthesis in liver. The impact of eNOS on glucose
metabolism and insulin sensitivity is supported by its capacity to increase the
transport of insulin and glucose to key peripheral tissues such as skeletal muscle
and to regulate gluconeogenesis. Additionally, there may be implications for
eNOS-mediated HISS release, which enhances the vasodilatory properties of
insulin. That eNOS prevents hyperinsulinemia in two separate genetic gain-offunction studies

160, 544

suggests further that it could impact glucose metabolism

directly by modulating insulin release. Other isoforms of NOS appear to promote
deleterious changes in metabolism. In the brain, evidence suggests that nNOSderived NO promotes hyperphagia.

The iNOS isoform promotes insulin

resistance in both liver and skeletal muscle and is critical in inflammatory
responses in multiple tissues, most notably, the adipose organ. In contrast to
eNOS, iNOS appears to promote gluconeogenesis, and iNOS has remarkable
effects on cytokine-mediated insulin secretion. Collectively, it is apparent that NO
is one of the most critical regulators of metabolism, body composition, and insulin
sensitivity. Harnessing its beneficial metabolic actions is an exciting prospect for
combatting metabolic disease in the future.
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Figure 43. Working model of the systemic effects of NO on obesity and
metabolism. Illustration of major organs and processes affected by NO and
nitrogen oxides derived from eNOS, nNOS, and iNOS:

The eNOS isoform

shows anti-obesogenic and insulin sensitizing effects, which appears to be based
in the ability of the enzyme to decrease lipid synthesis and promote fat oxidation
in the liver and skeletal muscle. Additionally, eNOS may be implicated in the
secretion of hepatic insulin sensitizing substance (HISS), which might support
insulin sensitivity in peripheral tissues such as skeletal muscle. eNOS is
important also for maximizing delivery of insulin and substrates to skeletal
muscle, and this is likely critical in regulating insulin sensitivity and glucose
tolerance. Through its actions in liver and pancreas, eNOS may also suppress
gluconeogenesis and prevent hyperinsulinemia, respectively. Additionally, NO
increases the abundance of mitochondria and stimulates substrate oxidation
capacity in adipose tissue, effectively promoting “browning” of white adipocytes.
Conversely, other isoforms of NOS appear to have a more malevolent role in
metabolism. NO derived from nNOS promotes hyperphagia, and iNOS-derived
nitrogen oxides can promote insulin resistance and inflammation in key
peripheral tissues such as liver, skeletal muscle, and adipose tissue. In addition,
iNOS may affect glucose homeostasis by increasing glucose output from the liver
and by impairing the exocrine and endocrine activities of the pancreas.
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